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Abstract
Chronic kidney disease (CKD) comprises a group of pathologies in which the renal excretory function is chronically
compromised. Most, but not all, forms of CKD are progressive and irreversible, pathological syndromes that start
silently (i.e. no functional alterations are evident), continue through renal dysfunction and ends up in renal failure.
At this point, kidney transplant or dialysis (renal replacement therapy, RRT) becomes necessary to prevent death
derived from the inability of the kidneys to cleanse the blood and achieve hydroelectrolytic balance. Worldwide,
nearly 1.5 million people need RRT, and the incidence of CKD has increased significantly over the last decades.
Diabetes and hypertension are among the leading causes of end stage renal disease, although autoimmunity, renal
atherosclerosis, certain infections, drugs and toxins, obstruction of the urinary tract, genetic alterations, and other
insults may initiate the disease by damaging the glomerular, tubular, vascular or interstitial compartments of the
kidneys. In all cases, CKD eventually compromises all these structures and gives rise to a similar phenotype
regardless of etiology. This review describes with an integrative approach the pathophysiological process of
tubulointerstitial, glomerular and renovascular diseases, and makes emphasis on the key cellular and molecular
events involved. It further analyses the key mechanisms leading to a merging phenotype and pathophysiological
scenario as etiologically distinct diseases progress. Finally clinical implications and future experimental and
therapeutic perspectives are discussed.
Introduction to chronic kidney disease
Definition and clinical course
C h r o n i ck i d n e yd i s e a s e( C K D )c o m p r i s e sag r o u po f
pathologies in which the renal excretory function is
chronically compromised, mainly resulting from damage
to renal structures. Most, but not all, forms of CKD are
irreversible and progressive. Renal damage includes
(i) nephron loss due to glomerular or tubule cell deletion,
(ii) fibrosis affecting both the glomeruli and the tubules,
and (iii) renal vasculature alterations. CKD results from a
variety of causes such as diabetes, hypertension, nephritis,
inflammatory and infiltrative diseases, renal and systemic
infections (e.g. streptococcal infections, bacterial endocar-
ditis, human immunodeficiency virus -HIV-, hepatitis B
and C, etc.), polycystic kidney disease, autoimmune dis-
eases (e.g. systemic lupus erythematosus), renal hypoxia,
trauma, nephrolithiasis and obstruction of the lower
urinary ways, chemical toxicity and others. In a variable
number of cases, renal injury by any of these causes
evolves towards a chronic, progressive and irreversible
stage of increasing damage and renal dysfunction wherein,
eventually, renal replacement therapy (RRT, namely dialy-
sis or renal transplant) becomes necessary [1,2].
Whether started as glomerular, tubular or renovascu-
lar damage, chronic progression eventually converges
into common renal histological and functional altera-
tions affecting most renal structures, which lead to pro-
gressive and generalized fibrosis and glomerulosclerosis.
Once initiated, kidney injury gradually aggravates even
in the absence of the triggering insult. Congruently with
a common chronic phenotype, CKD can be diagnosed
independently from the knowledge of its cause. The
National Kidney Foundation (NKF) of the United States
of America classifies CKD progression in five stages
according to the extent of renal dysfunction and renal
damage, symptomatology and therapeutic guidelines
(table 1). Late stage 4 and, especially, stage 5 (renal fail-
ure) pose a heavy human, social and economic burden
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reproduction in any medium, provided the original work is properly cited.[3-6]. Figure 1 depicts the time course of key pathologi-
cal events [i.e. percentage of nephrons functionally
active, overall renal excretory function and glomerular
filtration rate (GFR)] and plasma and urine markers, as
they appear through the different stages of CKD.
The term uremia or uremic syndrome refers to the
clinical manifestations of CKD, which are derived from
the inability of the kidneys to properly clear the blood
of waste products. As a consequence, toxic substances
usually eliminated through the urine become concen-
trated in the blood and cause progressive dysfunction of
many (virtually all) other tissues and organs, seriously
compromising well-being, quality of life and survival.
For example, elevated serum uric acid is a marker for
decreased renal function, may have a mechanistic role
in the incidence and progression of renal functional
decline [7,8]. In a recent study performed on 900
healthy normotensive, adult blood donors higher serum
uric acid levels were highly significantly associated with
a greater likelihood of reduced glomerular filtration [9].
Further clinical trials are needed to determine if uric
acid lowering therapy will be effective in preventing
CKD. However, kidney damage must occur to a signifi-
cant extent before function becomes altered. Uremic
signs and symptoms start to be vaguely detectable when
at least two thirds of the total number of nephrons is
functionally lost. Until then, CKD runs apparently silent.
This is due to the ability of the remaining nephrons to
undergo hypertrophy and functionally compensate for
those that are lost [10].
A representation of GFR evolution in time is a helpful
estimation of renal disease progression rate. It is useful
to monitor CKD as well as to predict the time for RRT.
Progression rate is highly dependent on the underlying
cause but, due to genetic heterogeneity, it is also very
variable among subjects with the same etiology [2]. In
general, tubulointerstitial diseases progress more slowly
than glomerular ones, and also than diabetic kidney dis-
ease, hypertension-associated disease and polycystic kid-
ney disease. A complete diagnosis includes detection,
determination of stage of disease, assessment of etiology,
presence of comorbid conditions and estimation of pro-
gression rate [3-6].
The key and yet unmet issue in CKD is why, and
through which mechanisms, persistence of triggering
damage or repetitive bouts, initially repairable as in
acute damage events, eventually go beyond a no return
point, after which non reversible chronicity ensues. The
Table 1 Stages of chronic renal disease defined by the National Kidney Foundation of the U.S.A. according to the
glomerular filtration rate (GFR, in mL/min per 1.73 m
2 of body surface), and common manifestations observed
in each stage
Stage GFR Common symptoms
1 ≥ 90* -
2 60-90* ↑ Parathyroid hormone, ↓renal calcium reabsorption
3 30-59 Left ventricular hypertrophy, anemia secondary to erythropoietin deficiency
4 15-29 ↑ Serum triglycerides, hyperphosphatemia, hyperkalemia, metabolic acidosis, fatigue, nausea, anorexia, bone pain
5 < 15 Renal failure: severe uremic symptoms
*CKD is defined as either GFR < 60 mL/min/1.73 m
2 for 3 months or a GFR above those values in the presence of evidence of kidney damage such as
abnormalities in blood or urine (e.g proteinuria) tests or imaging studies. ↑: increase; ↓: decrease.
Figure 1 Graphic representation of the evolution of key
pathological events, such as percentage of nephrons
functionally active, overall renal excretory function and
glomerular filtration rate, and plasma and urine markers
associated with time course of chronic kidney disease. The
figure shows the relative priority of appearance of these elements
with repect to one another as it occurs in most cases of chronic
kidney diseases. Their appearance, however, may vary from this
general prototype in specific diseases or in determined cases. In the
same way, the slope of increase or decline may also vary. RRT: renal
replacement therapy, BUN: blood urea nitrogen, NAG: N-acetyl-b-D-
glucosaminidase.
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knowledge of CKD pathology. The development of early
diagnostic and prognosis markers, and effective, curative
-not merely palliative or delaying- therapies critically
depend on our finding answers to these largely ignored
questions. Notwithstanding, knowledge has emerged in
the last few decades on new mechanisms and molecular
pathways that mediate the development of certain facets
of chronic phenotypes. This knowledge is potentially
useful for optimizing current therapies and for develop-
ing new ones. The purpose of this review is to describe
the pathophysiological processes leading to tubular,
interstitial, glomerular and renovascular chronic dis-
eases, focused on the cellular and molecular mechan-
isms involved, making emphasis in those that are
common for most CKDs regardless of aetiology.
Etiopathogenesis
A variety of renal injuries may eventually evolve to CKD
[2]. Disease may start in the tubules and interstitium
(tubulointerstitial diseases), in the glomeruli (glomerular
diseases) or even in the renal vascular tree (renovascular
diseases), as a consequence of (i) systemic diseases such
as diabetes and hypertension, (ii) autoimmune reactions
and renal transplant rejection, (iii) the action of drugs,
toxins and metals, (iv) infections, (v) mechanical
damage, (vi) ischemia, (vii) obstruction of the urinary
tract, (viii) primary genetic alterations, and (ix) undeter-
mined causes (idiopathic). Yet, a number of conditions,
like genetic cystic diseases, affect renal structures and
function through mostly unspecific mechanisms, and
evolve into CKD for undetermined reasons.
Some decades ago, the leading cause of CKD was glo-
merulonephritis secondary to infections. Antibiotics and
improved sanitary conditions have laid the way to dia-
betes and hypertension as the first and second leading
causes of end stage renal disease (ESRD) in the devel-
oped world, respectively [11]. In fact, about 50% of
ESRD patients (in the USA) are diabetic [12]. According
to this source, about 50-60% of all patients with CKD
are hypertensive, and this figure increases to 90% in
patients over 65 years. In the corresponding general
population the incidence of hypertension is 11-13% and
50%, respectively. Alltogether, 70% of ESRD cases are
due to diabetes and hypertension [13]. Recently, several
large-scale epidemiological studies [14-16] have identi-
fied obesity as an independent risk factor for CKD. The
link between obesity and CKD is not fully explained by
the association between obesity and diabetes or hyper-
tension respectively [17]. Hall et al. [18] described a pro-
gressive increase in the incidence of ESRD since the
eighties, coinciding with an increase in obesity and
decreased hypertension. Similarly, Chen et al. [19]
showed an association between the metabolic syndrome
and the risk of developing chronic renal failure. Both
studies support the association between increased
weight and kidney disease, although no direct causality
link between obesity and CKD can yet be established
[20].
Genetic predisposition
A genetic predisposition for renal failure is demon-
strated by the 3-9 times higher probability of ESRD in
patients with a family history of CKD, compared to the
general population [21]. However, it is difficult to assess
whether this predisposition is due to a specific suscept-
ibility to undergo renal damage, or to other comorbid
conditions generally accepted to have poly- or oligo-
genetic components, like hypertension, diabetes or
atherosclerosis. Still, this observation has launched the
search for nephropathy susceptibility genes.
Except for monogenic diseases (e.g. polycystic renal
disease) [22], genetic studies based on quantitative trait
loci (QTLs) analysis and sub-pair analysis have been
unable to demonstrate polymorphism associations valid
for most forms of CKD. A number of polygenic minor
gene-gene interactions have been associated with specific
human CKD of different etiology, such as type 2 diabetic
nephropathy [23]. Several loci have been identified on
chromosome 3q, 10q and 18q for diabetic nephropathies,
and on 10q also for non-diabetic nephropathies [24].
Recently MYH9 gene polymorphisms have been shown
to account for much of the excess risk of HIV-associated
nephropathy, hypertensive, diabetic and nondiabetic kid-
ney disease in African Americans [25-27]. A number of
mutations have been associated to focal and segmental
glomerulosclerosis during the last decade including:
(i) two polimorphisms of apolipoprotein L 1 (APOL1)
have been associated to the disease in African descen-
dents [28]; and (ii) genetic alterations in five proteins
expressed in podocytes, namely podocin (NPHS2 gene)
[29,30], inverted formin (INF2 gene) [31], the transient
receptor potential cation channel, subfamily C, member
6 (TRPC6 gene) [32], CD2 associated protein (CD2AP
gene) [32], and alpha-actinin 4 (ACTN4 gene) [32].
Genetic analysis of renal damage-prone rats crossed
with more resistant strains have revealed the existence
of 15 loci associated with renal disease [33], three of
which coincide with those found in human monogenic
segmental glomerulosclerosis, Pima Indians kidney
disease, and creatinine clearance impairment in African-
and Caucasian-Americans [34,35]. These studies high-
light the potential predictive value of animal models for
the identification of CKD-associated genes. Still, other
genetic determinants present in humans and absent in
most animal models, derived from the inter-race, inter-
population and inter-individual genomic heterogeneity,
may pose limitations to findings make in animals.
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dency of renal disease prevalence has been demon-
strated in several studies with human populations
surveyed for e.g. diabetic nephropathy [36,37] or mem-
branous glomerulonephritis [38].
Tubular diseases
The terms tubular diseases, tubulointerstitial diseases,
tubulointerstitial nephritis and tubulointerstitial nephro-
pathies refer to a heterogeneous panel of alterations
which primarily affect both cortical and medullary
tubules and the interstitium, and secondarily other renal
structures such as the glomeruli [39]. Tubules are the
main component of the renal parenchyma and receive
the most part of injury in renal disease [39]. Neverthe-
less, renal interstitium also plays an important role in
tubulointerstitial nephropathies, since pathogenesis per-
petuates in this compartment and interstitial alterations
contribute to diminish renal function [40]. The intersti-
tium is formed by the intercellular scaffolding posed by
the extracellular matrix (ECM) and basement mem-
branes, in which several cell types can be found. Apart
from those forming blood and lymphatic vessels, includ-
ing microvascular pericytes, resident and infiltrated
immune system cells can also be found (i.e. white blood
cells including macrophages). Finally, fibroblasts and,
especially under pathological conditions, myofibroblasts
form part of the tubular interstitium. Primary tubuloin-
terstitial diseases [41] are idiopathic, genetic or due to
(i) the chemical action of toxics and drugs that accumu-
late in the tubules inducing apoptosis or necrosis of
tubular epithelial cells; (ii) infection and inflammation of
the tubulointerstitium as a result of reflux/chronic
pyelonephritis or other causes; (iii) increased intratubu-
lar pressure induced by mechanical stress and related to
obstruction of lower urinary tract caused by lithiasis,
prostatitis, fibrosis, or retroperitoneal tumors; and
(iv) transplant rejection due to immune response. In
many cases, the cause of the disease remains unknown.
Renal function progressively deteriorates as a conse-
quence of dysfunctional processes of tubular reabsorp-
tion and secretion, activation of tubular cells with
recruitment of inflammatory mediators, progressive
tubule loss and tissue scarring, and eventual damage of
other renal structures (e.g. the glomeruli).
Independently of the triggering cause, characteristic
hallmarks of tubulointerstitial diseases are tubular atro-
phy, interstitial fibrosis and cell infiltration [39], result-
ing in a significant increment in interstitial volume
[42,43]. In early stages, glomerular filtration becomes
slowly altered, and tubular dysfunction constitutes the
main manifestation of tubulointerstitial nephropathies
[39,44]. In contrast to glomerular diseases, in tubuloin-
terstitial diseases hypertension appears late and only
after a significant fall of GFR [45-47]. Proximal tubule
alterations induce bicarbonaturia, b2-microglobulinuria,
glucosuria and aminoaciduria. Distal alterations induce
tubular acidosis, hyperkalemia and sodium loss [48].
Structural alterations in medulla cause nephrogenic dia-
betes insipidus that is clinically manifested as polyuria
and nocturia [49].
Tubulointerstitial diseases can be considered as perpe-
tuating inflammatory responses that escape normal
defense and restorative mechanisms [50]. The immune
response includes recognition of the insult, an integra-
tive phase and an executioner response. This response is
carried out by the complex, integrated and coordinated
participation of tubular epithelial, interstitial and infil-
trated cells. This process is mediated by chemotactic,
proinflammatory, vasoactive, fibrogenic, apoptotic, and
growth-stimulating cytokines and autacoids, which are
released by participating cells, as well as by overexpres-
sion of specific receptors for these molecules, and anti-
genic and adhesive surface markers expressed in target
cells [51-55]. The sequence of pathogenic events during
tubulointerstitial fibrosis starts with the initial damage
that activates inflammatory and repair mechanisms in
the kidneys, and follows with a stage of fibrosis that
leads to progressive tissue destruction (figure 2). These
events are described in the next sections.
Initial damage and cell activation
As a consequence of the damage inflicted to tubular
structures by the triggering insult, an initially restorative
response starts, which eventually corrupts into a patho-
logical vicious cycle of interstitial fibrosis and tissue
destruction. Depending on the insult, tubular epithelial
cell necrosis, apoptosis, or both are observed. In a
restorative effort, an inflammatory response is imple-
mented and tubular cells proliferate to substitute for
dead cells. For unknown reasons, under undetermined
circumstances the restorative process (in this and the
next phases -see below-) loses the appropriate regulation
and takes an irreversible self-destructive course that
does not need the presence of the initial insult to
progress. Interstitial fibrosis results from a deregulated
process of fibrogenesis initially required to rebuild the
normal tissue structure posed by ECM and basement
membranes [56]. Rather early, interstitial fibrosis gains a
central pathological role, scars the interstitium and
epithelial areas that should have been repaired with new
epithelial tubular cells, and induces further tissue
damage and destruction through apoptosis and phenoty-
pical transdifferentiation of epithelial tubular cells.
Tubular epithelial cells respond to the initial insult by
(i) proliferating or (ii) dedifferentiating through an
epithelial to mesenchymal transition (EMT)-like process
that allows them to migrate, proliferate and eventually
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blasts is an undetermined mechanism of fibrosis. It is
often recognized as an important contributor to fibrosis
[59-61], although this concept has been challenged (see
t h ed e b a t ei n6 2 ) .E v e n m o r e ,i nt h ef i b r o s i so b s e r v e di n
the transition from acute kidney injury to CKD, myofi-
broblast have been shown to be mostly originated from
fibroblasts and pericytes and not from tubule epithelial
cells [63,64]. As commented above, the skewed repair
process gives way to a fibrotic process mediated by
Figure 2 Schematic depiction of the pathological process of tubular degeneration and tubulointerstitial fibrosis characteristic of
tubulointerstitial diseases, and also of later stages of glomerular and renovascular diseases leading to chronic kidney disease
(adapted from references [87]and [291]). EMT, epithelial to mesenchymal transition.
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fibroblasts [57] and by secretion of (i) cytokines that
attract mononuclear cells, (ii) growth factors that stimu-
late interstitial fibroblasts, and (iii) proinflammatory and
profibrotic molecules that stimulate the synthesis of
both basement membrane and tubulointerstitial ECM
proteins, such as collagens I and IV, fibronectin and
laminin [65,66]. Critical events acting on tubular epithe-
lial cells induce the early deposition and accumulation
of ECM components in the interstitial compartment.
Apical stimulation is exerted on the tubular epithelium
by mechanical or chemical action of the glomerular
ultrafiltrate, derived from an increased GFR per indivi-
dual remnant nephron resulting in an increased filtra-
tion of proteins, chemokines, lipids and hemoproteins
[65]. Basolateral stimulation originates from mononuc-
lear cells and from hypoxia and ischemia resulting from
postglomerular capillary loss. Peritubular capillary loss
has been demonstrated in animal models of CKD, which
has been associated to tubulointerstitial ischemia and
fibrosis [67]. It has been suggested that capillary loss is
the result of NO synthesis inhibition, because hydrolysis
of the endogenous NO synthase inhibitor asymmetric
dimethylarginine (ADMA) with exogenous dimethylargi-
nine dimethylaminohydrolase, reduces the extent of
capillary loss and renal damage [67]. Indeed, capillary
loss is a pathological mechanism associated to CKD pro-
gression and nephron loss [68]. A number of mediators
are known to participate in these tubular events, which
are summarized in table 2 (see also figure 3).
Infiltrated cells, spanning the endothelium of peritub-
ular capillaries [69], or proliferating resident macro-
phages [70], essentially contribute to the progression of
renal parenchymal damage in CKD [50]. Chemoattrac-
tans secreted from the basolateral membrane of
damaged tubular cells or crossing the tubule wall from
the luminal filtrate, recruit inflammatory cells (mono-
cytes and lymphocytes) and induce fibroblast prolifera-
tion. This event, in turn, potentiates a vicious circle of
inflammation and fibrogenesis [71]. Specifically, acti-
vated tubular cells synthesize the chemoattractant cyto-
kine MCP-1 as a response to protein overload [72].
Tubular MCP-1 production has been documented in
patients with CKD [73] and animal models [74]. MCP-1
may also proceed from the proteinuric glomerular ultra-
filtrate, originating in plasma or damaged glomeruli.
Importantly, MCP-1-deficie n tm i c eu n d e r g oam i l d e r
interstitial inflammation and show a higher life expec-
tancy than controls during CKD [74]. Interstitial accu-
mulation of monocytes and activation of resident
macrophages amplify the inflammatory response and
lymphocyte diapedesis [69], and contribute to damage
progression as sources of profibrotic factors [50].
Damage also activates renal fibroblasts, which prolifer-
ate and constitute an important source of pathological,
fibrogenic ECM components, such as collagens and
fibronectin [42,61,75,76] in response to many factors
released from primed tubular cells, white cells and fibro-
blasts themselves. These molecules include cytokines and
growth factors, such as transforming growth factor beta1
(TGF-b1), MCP-1, connective tissue growth factor
(CTGF), insulin-like growth factor (IGF), platelet-derived
growth factor (PDGF), platelet activating factor (PAF),
and interleukins (ILs) 1, 4 and 6, as well as vasoactive
molecules (e.g. angiotensin II and endothelin-1), and
ECM-cell interaction molecules (e.g. integrins, hialuronic
acid) [[65]; table 2; figure 3].
In most forms of CKD, the number of interstitial myofi-
broblasts is increased, and strongly correlates with the
degree of interstitial fibrosis [77,78]. Activated myofibro-
blasts constitute a predicting histological marker for the
progression of renal disease [79,80]. Myofibroblasts are the
main source of excessive ECM in fibrotic nephropathies
[51]. Myofibroblasts may be originated by trans-differen-
tiation of fibroblasts, tubular epithelial cells, vascular peri-
cytes and macrophages [57,81,82]. In diseased kidneys,
myofibroblasts accumulate around damaged tubules and
arterioles. Fibrosis-induced microvascular obliteration and
vasoconstriction is mediated by vasoactive factors (e.g.
angiotensin II and endothelin-1), which produce ischemia,
glomerular hemodynamic alterations and further angio-
tensin II production, all of which amplify fibrogenesis and
perpetuate damage [83,84] with the concourse of TGF-b1
and PDGF [85,86].
Fibrosis
Under pathological conditions during CKDs, damaged
renal tissue is replaced by a scar-like formation, charac-
terized by excessive ECM accumulation and progressive
renal fibrosis. Fibrosis is the consequence of (i) an
increased synthesis and release of matrix proteins from
tubular cells, fibroblasts and mostly myofibroblasts, and
(ii) a decreased degradation of ECM components [87,88].
During progression of tubulointerstitial fibrosis, fibro-
blasts show a higher proliferation rate, differentiation to
myofibroblasts, and alteration of ECM homeostasis [42].
Although in wound-healing studies it has described an
antifibrotic role for macrophages due to their participa-
tion in the resolution of the deposited ECM through pha-
gocytosis [89], many short-term studies relate the
number of infiltrated macrophages with the extent of
fibrosis and kidney dysfunction [reviewed in [90]], sup-
porting an etiological role of these cells in the pathogen-
esis of renal damage. Moreover, attenuated accumulation
of macrophages in experimental obstructive nephropathy
is accompanied by enhanced renal interstitial fibrosis and
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reveal a reciprocal relationship between these two para-
meters and raise some questions about the function of
infiltrating cells [92]. Thus, probably machrophages play
a dual effect, with a short-tem profibrotic effect, and a
long-term healing effect.
The interstitial wound in the fibrotic kidney is formed
by excessive deposition of constituents of the interstitial
matrix (e.g. collagen I, III, V, VII, XV, fibronectin), com-
ponents restricted to tubular basement membranes in
normal conditions (collagen IV and laminin), and de
novo synthesized proteins (tenascin, certain fibronectin
isoforms and laminin chains) [93]. Fibronectin, with
chemoattractant and adhesive properties for the recruit-
ment of fibroblasts and the deposition of other ECM
components [94], is one of the first ECM proteins to
Table 2 Main molecular mediators known to participate in the pathophysiological process of tubular degeneration
and interstitial fibrosis, grouped according to their most important effect
ENDOGENOUS ACTIVATORS ORIGIN FBR & EMT INF TD ISCH REFERENCES
1. Fibrosis and EMT
TGF-b TC, F, MF, P, iG X EMT [252,253]; secretion of profibrotic MCP-1 [254] and CTGF
[255]. Fibrosis: ↑ECM components and PAI, and ↓MMPs
[51,104-106]
EGF P, UF X EMT [256]
FGF P, UF X EMT [234]; fibrosis [87,257-259]
PDGF P, RC X Fibroblast to myofibroblast transformation [87], proliferation of
myofibroblasts [260]
CTGF TC X X EMT, fibrosis, apoptosis [255,261,262]
SPARC TC, F, MF X ↓cell adhesion and proliferation, activates TGF-b and collagen I
and fibronectin synthesis [98,263]
Thrombospondin TC, F, MF X Activates TGF-b [99]
Decorin and biglycan TC, F, MF X Reservoires of bFGF and TGF-b [101,102].
Collagen I F, MF, TC X EMT [264]
PAI-1 TC, F, MF X ECM accumulation and fibrosis [265]
TIMP-1 TC, F, MF X Fibrosis ? [87,108]
2. Inflammation
Complement C3 and C4 P, TC X X Inflammation and fibrosis [266-269]
MCP-1 TC, P, iG X X Cell infiltration, fibrosis [72,74,254]
ICAM-1 and VCAM-1 EC, TC X On EC: diapedesis and infiltration [270]; On TC: uncertain
[271,272]
Hialuronic acid TC, F, MF X Inflammation, MCP-1 and secretion of adhesion molecules
[97,98]
3. Tubular damage
Protein overload UF X Tubule cell activation [65] and release of ET-1 [273], ANG-II [274],
MCP-1, and RANTES [275]
Complement C5b-9 P X X Tubular damage and fibrosis [276]
TNF-a, IFN-g, Tweak iWBC X X X Inflammation, cell death, fibroblast and myofibroblast activation
[277-279]
4. Ischemia
Endothelin-1 TC X X Vasoconstriction and ischemia [273,280]; ↑ECM components and
TGF-b [87]
RAS EC, TC, P X Vasoconstriction, ischemia and TGF-b secretion [87,281-284]
ADMA Plasma X X Vasoconstriction [67]
ENDOGENOUS INHIBITORS ORIGIN FBR & EMT INF TD ISCH REFERENCES
1. Fibrosis and EMT
Collagen IV F, MF, TC X Inhibits EMT [285]
MMP-2 and 9 TC X Degrade collagen IV [286]
HGF P X Inhibits EMT and fibrosis [287-290]
BMP-7 P, TC? X Inhibits EMT and fibrosis [285]
ADMA: asymmetric dimethylarginine; EC: endothelial cells; F: fibroblasts; iG: inflamed glomeruli; iWBC: infiltrated white blood cells; MF: myofibroblasts; P: plasma;
RC: renal cells (unspecified); TC: tubular cells; UF: glomerular ultrafiltrate.
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blasts, myofibroblasts, macrophages, mesangial and tub-
ular cells are sources of fibronectin in inflammation and
fibrogenesis [95,96]. Other upregulated components in
the interstitium of fibrotic kidneys are hialuronic acid
[97,98], secreted protein acidic and rich in cysteine
(SPARC; 98), thrombospondin [99,100], decorin and
biglycan [101,102] (see table 2 and figure 3).
Certain types of CKD are caused by a marked altera-
tion of renal collagenase activity with small or no
changes in collagen synthesis. Renal fibrosis in mice
with ureteral obstruction is also the result of decreased
collagenolytic activity [103]. In damaged kidneys, upre-
gulation of TGF-b activation also contributes to override
the natural ECM homeostatic equilibrium by downregu-
lating the expression of determined MMPs and
activating the expression of the MMP-inhibitor plasmi-
nogen activator inhibitor 1 (PAI-1; 51,104-106). Also
TIMP-1, an endogenous tissue inhibitor of MMPs, is
actively synthesized by renal cells in progressive CKD
[107], and its expression is stimulated by TGF-b,T G F -
a, epithelial growth factor (EGF), platelet-derived
growth factor (PDGF), tumor necrosis factor alpha
(TNF-a), interleukins 1 and -6, oncostatin M, endo-
toxin, and thrombin [87]. However its role is controver-
sial because TIMP-1 deficient mice show no significant
differences in interstitial fibrosis during induced renal
damage [87,108].
Progressive tissue destruction
Tubular atrophy is a histological feature of progressive
CKD [109]. Excessive accumulation of ECM, together
Figure 3 Extracellular mediators and effectors of tubulointerstitial pathological events in chronic kidney disease.A D M A :a s y m m e t r i c
dimethylarginine. HA, hyaluronic acid. C3 and C4, factors 3 and 4 of the complement. UF, ultrafiltrate.
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space, has destructive effects on renal parenchyma and
renal function [109]. Loss of tubular cells occurs during
the destructive phase as a consequence of apoptosis,
persistent EMT (with an undetermined contribution),
and interstitial scarring [110]. At this stage, unbalanced
fibrogenesis may also contribute to tubular cell death.
Interstitial fibrosis impairs oxygen supply to tubular and
interstitial cells, which leadso rs e n s i t i z e st oa p o p t o s i s
[111]. A relevant apoptosis effector in CKD is the Fas-
initiated extrinsic pathway [112]. In fact, attenuated
expression of the apoptosis-mediated receptor Fas and
the endogenous agonist Fas ligand (FasL) reduced
tubular epithelial cell apoptosis in an in vivo model of
diabetic nephropathy [113]. However, in normal circum-
stances, many epithelial cell types, including renal
tubular epithelial cells, are refractory to Fas stimulation-
induced apoptosis [114]. Inadequate Fas clustering and
altered equilibrium of pro- and anti-apoptotic intracellu-
lar modulators may explain the lack of sensitivity to Fas
[115,116]. Specifically, signaling at the level of the
death-induced signaling complex (DISC) formed around
Fas upon receptor stimulation is due to basal expression
of Fas-associated death domain-like IL-1-converting
enzyme-like inhibitory protein (FLIP), an endogenous
inhibitor of DISC [117]. FLIP antisense or cycloheximide
treatment, which also drastically reduces cellular levels
of FLIP, make refractory fibroblasts to undergo apopto-
sis upon Fas stimulation. Accordingly, priming stimula-
tion is necessary to make epithelial tubule cells sensitive
to Fas-mediated apoptosis, as it occurs in CKD.
TGF-b intervenes in tubule apoptosis in vivo as
demonstrated by the reduced apoptosis after treatment
with an anti TGF-b1 antibody in rats with ureteral
obstruction [86-118]. Given its central role in CKD [110],
TGF-b poses a good candidate for priming tubular cells
to Fas-induced apoptosis. Another candidate for mediat-
ing sensitization to Fas-induced apoptosis is angiotensin
II. In vivo, inhibition of angiotensin II results in a strong
amelioration of CKD-associated damage, including tubu-
lar epithelial cell apoptosis [119]. In vitro, angiotensin
II induces apoptosis in rat proximal tubular epithelial
cells, and this effect is mediated through the synthesis of
TGF-b followed by the transcription of the cell death
genes Fas and FasL [120]. In this setting, treatment of
tubular epithelial cells with an anti TGF-b neutralizing
antibody partially inhibits, while an anti FasL antibody
strongly inhibits angiotensin II-induced apoptosis. IL-1
and hypoxia also induce an upregulation of Fas expres-
sion in tubule cells [121-123]. Very recently, it has been
shown that confined tubular overexpression of TGF-b in
mice produces massive proliferation of peritubular cells,
widespread fibrosis and focal nephron loss associated to
tubular cell dedifferentiation and autophagy [124],
although the role of autophagy in tubule cell death needs
to be further explored.
The interplay of these and other factors need to be
further explored in order to understand the onset of apop-
tosis in tubular cells during CKD [125]. Furthermore,
angiotensin II is a regulator of renal cell function, includ-
ing tubular cells under physiological conditions [126]. This
duality could be related to the fact that cell-to-cell and
ECM-to-cell interactions, asw e l la ss p e c i f i ch u m o r a l
determinants present in different pathophysiological cir-
cumstances condition the effect of angiotensin II on cell
fate and function. For example, the collagen discoidin
domain receptor I is involved in survival of tubular
Madin-Darby canine kidney (MDCK) cells [127]. As such,
an excessive collagen I and fibronectin deposition may
alter cell sensitivity to apoptosis [128]. A number of cir-
cumstances must hypothetically be present to let angioten-
sin II (and other mediators) induce apoptosis in vivo,s u c h
as a determined humoral coactivating context, and ECM
homeostatic disruption caused by fibrogenesis. Probably,
persistence of angiotensin II contributes to generate these
permissive phenotypes. Finally, ischemia may also directly
induce or sensitize tubular epithelial cells to apoptosis and
necrosis [129,130], or indirectly through promotion of
fibrogenesis. In fact, culture of tubular cells in hypoxic
conditions reduces MMP activity and increases total col-
lagen content [131]. Also, in experimental CKD, hypoxia-
inducible factor (HIF) has been shown to mediate
hypoxia-induced fibrosis [132,133]. Fibrosis also affects the
diseased renal vascular tree by reducing the lumen of indi-
vidual vessels and peritubular capillary cross sectional area
[134]. Figure 3 depicts a prototypical tubulointerstitial
situation showing the most important extracellular media-
tors of key pathological events.
Glomerular diseases
Glomerulopathies are renal disorders affecting glomeru-
lar structure and function. Primary glomerulopathies
encompass inflammatory glomerular diseases (glomeru-
lonephritis) and non-inflammatory glomerulopathies
[135]. In addition, secondary glomerulopathies result
from primary tubulointerstitial and renovascular dis-
eases, which contribute to the progression of the
damage [95]. Primary inflammatory and non-inflamma-
tory conditions give rise to the nephritic and nephrotic
syndromes, respectively [135]. Diabetes, hypertension
and glomerulonephritis represent the major causes of
chronic renal failure in glomerular diseases [136].
Inflammatory glomerular diseases are due to (i)
systemic and renal infections; (ii) focal and segmental
glomerulonephritis; (iii) glomerular basement membrane
damage resulting from immune deposits in the capillary
wall (lupus nephritis, membranoproliferative glomerulo-
nephritis), accumulationo fI g Ac o m p l e x e si nt h e
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culitic glomerulonephritis. Glomerulonephritis involves
glomerular inflammation. Cellular and humoral immune
responses participate in this injury, which involve circu-
lating and in situ-formed immunocomplexes [137], and
complement pathways [138], which tend to accumulate
in the components of the filtration barrier and to dis-
rupt its structure. A major consequence of glomerulone-
phritis is the nephritic syndrome characterized by
hematuria and proteinuria (due to alterations in the glo-
merular filtration barrier) and by reduced glomerular
filtration, oliguria and hypertension due to fluid
retention [139]. Additional characteristic hallmarks
of glomerulonephritis include the activation and
proliferation of mesangial cells [135] and endothelial
cells [140], which contribute to the fibrosis and
sclerotic scar lesions commonly observed in damaged
glomeruli.
Non-inflammatory glomerular diseases comprise a
repertoire of metabolic and systemic diseases that chemi-
cally or mechanically damage the glomerulus, such as
diabetes and hypertension, toxins and neoplasias. Non-
inflammatory glomerular diseases also include idiopathic
membranous nephropathy because, although it results
from immune injury to the podocyte, glomerular inflam-
mation is not conspicuous, at least initially. Diabetes is
the leading cause of CKD and ESRD in developed coun-
tries, resulting in 20-40% of all patients developing ESRD
[141]. Persistent hypertension is another important trig-
ger of non-inflammatory glomerular disease, caused by
pathologic remodeling of the capillary tuft as a response
of an increased perfusion pressure and physical stress.
Although the autoregulatory capacity of renal blood flow
effectively protects the kidneys against hypertension, pro-
tection is mostly but not completely effective, and autore-
gulation partially fades away in a slow but progressive
manner [142]. The major clinical syndrome produced by
non-inflammatory glomerulopathies is the nephrotic syn-
drome. It presents with severe proteinuria (> 3 g/day),
hypoalbuminemia, oedema, hyperlipidemia and lipiduria
[139], with reduced or even normal glomerular filtration.
Contrarily to the nephritic syndrome, the nephrotic syn-
drome courses without hematuria. Yet, it must be
emphasized that even non-inflammatory glomerulopa-
thies course with renal inflammation, which is a key
mechanism of progression and an important target for
therapeutics [143]. The difference with inflammatory glo-
merulopathies is that inflammation is secondary to the
injury inflicted by the initiating cause.
Histopathological alterations and consequences
of the glomerular damage
Glomerular pathogenetic mechanisms are as diverse as
types of primary glomerulopathies. Dependent on the
aetiology, specific glomerular diseases course with a speci-
fic mix of renal histopathological findings or patterns,
including focal and segmental sclerosis, diffuse sclerosis,
mesangial, membranous or endocapillary proliferation,
membranous alterations and immune deposits, crescent
formations, thrombotic microangiopathy, vasculitis and
others. A determined glomerular disease may evolve
through different histopathological patterns. As an exam-
ple, diabetic nephropathy has been recently classified in
4 types: (i) Class I, characterized by isolated glomerular
basement membrane thickening and only mild, nonspeci-
fic changes by light microscopy; (ii) Class II, in which mild
(IIa) or severe (IIb) mesangial expansion is observed with-
out nodular sclerosis, or global glomerulosclerosis in more
than 50% of glomeruli. (iii) Class III, when nodular sclero-
sis or Kimmelstiel-Wilson lesions are present in at least
one glomerulus with nodular increase in mesangial matrix,
without changes described in class IV; and (iv) Class IV or
advanced diabetic glomerulosclerosis, characterized by the
presence of more than 50% of the glomeruli with global
glomerulosclerosis, and further clinical or pathologic evi-
dence ascribing sclerosis to diabetic nephropathy [144].
In most CKDs, sooner or later the selectivity and per-
missivity of the glomerular filtration barrier becomes
altered, and the glomerular structure collapses and leads
to sclerosis and scarring, reduced glomerular flow and
filtration, or even physical scission from the tubule
[[145], and figure 4]. Mesangial cell proliferation and
glomerulosclerosis, are also common features of most
established glomerulopathies [136,146,147]. Mesangial
proliferation is often considered an initial, adaptive
response that eventually loses control and develops into
a pathological process. Podocyte injury is another char-
acteristic of many glomerulopathies, and a central event
in proteinuric nephropathies [146,147]. Pathological
podocyte involvement is mainly the consequence of
(i) podocytopenia resulting from podocyte apoptosis and
EMT; or (ii) foot process effacement and alterations in
podocyte dynamics [146,148,149]. Podocytopenia is
believed to cause or favor the adhesion of a glomerular
capillary to Bowman’s capsule at a podocyte deprived
basement membrane point. These adhesions create gaps
in the parietal epithelium that allow ectopic filtration
out of Bowman’s capsule into the paraglomerular, inter-
stitial space, which may be extended over the glomeru-
lus and may also initiate tubulointerstitial injury (150;
see section 5).
Glomerular endothelial cells are also primary sites of
injury resulting in glomerulopathies and CKD. They will
be addressed in section 4, along with other renovascular
diseases. Besides thrombotic microangiopathy, glomerulo-
vascular diseases include atherosclerotic microembolia,
small vessel vasculitis, diabetic nephropathy, membrano-
proliferative and post-infectious glomerulonephritis, lupus
López-Novoa et al. Journal of Translational Medicine 2011, 9:13
http://www.translational-medicine.com/content/9/1/13
Page 10 of 26nephritis and the inherited disease familial hemolytic ure-
mic syndrome. In addition, the hemodynamic damage is
an important component of glomerulosclerosis and pro-
gressive glomerular injury in most forms of CKD. Hyper-
filtration, glomerular hypertension, glomerular distention
and inflammation occurring after the initial insult cause
diverse glomerular alterations that activate, and even
damage, mesangial and endothelial cells [[151]; see also
section 5].
Glomerular ECM deposition evolves in patients with
glomerulonephritis as the disease progresses [152]. As in
normal kidneys, no interstitial collagen I and III are
detected in patients with mild glomerulonephritic
damage [152]. Progressive renal damage correlates with
increasing presence of collagen IV and VI, laminin and
fibronectin in the mesangium. Finally, in later stages of
glomerulonephritis, the amount of collagen IV, laminin
and fibronectin gradually decreases, while focal expres-
sion of collagen I and III increases. Glomerular cell
apoptosis also occurs in parallel to sclerosis, and ECM
progressively scars the spaces left by dead cells [153].
Inflammation plays a pivotal role in the progression of
many, if not all, forms of CKD. In the glomerulus,
inflammation exerts different effects that amplify the
damage and directly contribute to the reduction in glo-
merular filtration (see section 3.2.). Initially, inflamma-
tion is probably activated as a repair mechanism upon
cellular and tissue injury. However, undetermined
pathological circumstances skew persistent inflammation
into a vicious circle of destruction and progression. In
fact, inflammation activates many renal cell types to
produce cytokines, which directly damage renal cells
and intensify inflammation.
Cells and molecular mediators involved
Mesangial cells are contractile glomerular pericytes that
play a major role in the regulation of renal blood flow
and GFR. They also have a pivotal participation in the
genesis of chronic glomerular diseases. Mesangial cell
proliferation is a common feature during the initial
phase of many chronic glomerular diseases, including
IgA nephropathy, membranoproliferative glomerulone-
phritis, lupus nephritis, and diabetic nephropathy [154].
Numerous experimental models of glomerular damage
have reported that proliferation of mesangial cells fre-
quently precedes and is associated with ECM deposition
in the mesangium and, therefore, to fibrosis and glomer-
ulosclerosis. In fact, reduction of mesangial cell prolif-
eration in glomerular disease models ameliorates ECM
deposition, fibrosis and glomerulosclerosis [154]. Thus,
proliferating mesangial cells are considered to be a cen-
tral source of ECM production in both focal and diffuse
glomerulosclerosis [155,156].
The fibrotic mechanism of renal damage in glomeru-
lopathies represents a final common pathway with the
initial glomerular insult starting a cascade of events that
include an early inflammatory phase followed by a fibro-
genic response in the glomerular and the tubulointersti-
tial compartments of the kidneys [93]. Several cytokines,
growth factors and complement proteins, through the
activation of nuclear factor-B( N F - B)-related
Figure 4 Schematic representation of the typical pathological
process of glomerular degeneration and sclerosis in
glomerular diseases. A, structure of a normal corpuscle showing
the Bowman’s capsule binding the glomerular capillary tuft, mainly
composed of endothelial and mesangial cells, podocytes and a
basal membrane. The very proximal segment of the tubule is also
depicted. B, an initial insult of undetermined nature produces a
focal lesion leading to podocyte loss and activation of an
inflammatory response involving circulating and resident inmmune
system cells. C, superseding the normal repair process, a
pathological response occurs, which commonly presents with
mesangial and Bowman’s capsule epiyhelial cell proliferation,
limphocyte extravasation and infiltration, fibrosis, and podocyte loss.
The ultrafiltration membrane becomes leakier and more permeable
to proteins. D, fibrosis extends damage through the corpuscle by
inducing apoptosis of epithelial cells and filling the spaces left by
dead cells, all of which give rise to pathways connecting the
Bowman’s capsule with the interstitium through with the protein
rich ultrafiltrate accesses other areas of the corpuscle and the
tubules and causes further damage.
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cells to release chemotactic factors [157]. As previously
reported, angiotensin II is one of the main effectors
implicated in resident cell activation in pathological kid-
ney [126]. Infusion of angiotensin II induces a marked
renal damage in glomeruli, tubulointerstitium and vas-
cular system, associated with cell proliferation, leukocyte
infiltration, interstitial fibrosis and modulation of
mesangial cell phenotype [158]. In the short-term,
angiotensin II acting on mesangial cells induces an
increase of cytosolic calcium and inositol phosphate,
prostaglandin synthesis and cellular contraction and
long-term alterations such as proliferation, hypertrophy
and ECM production [159]. These effects are mediated
by autocrine factors released upon angiotensin II action,
such as TGF-b1 [86,136,160]. TGF-b induces mesangial
cell proliferation directly and through the concourse of
PDGF [161]. PDGF appears to be an important mediator
of mesangial proliferation, and HGF counteracts PDGF
actions [162]. Several pathogenic molecules have been
additionally related to the development of glomerulo-
sclerosis, including endothelin [163] and reactive oxygen
species [164] that have also been implicated in angioten-
sin II-induced hypertrophy of mesangial cells [165].
Resident glomerular cells and circulating inflamma-
tory cells, including neutrophils, platelets and macro-
phages mediate inflammatory responses leading to
glomerular lesions [135,166,167]. Recruited inflamma-
tory cells amplify the fibrotic and proliferative response
of mesangial cells [168], and also the expression of the
EMT marker a-SMA [169], the production of ECM
components [155,170], and exacerbate cytokine and
growth factor release [171]. As explained for tubuloin-
terstitial diseases (sections 2.1. thru 2.3.), pro-inflam-
matory cytokines, including TNF-a,I L - 1a n do t h e r
interleukins, interferon gamma, tweak and others, are
known to be involved in paracrine actions resulting in
(figure 5):
(i)Direct cell injury and death [172,173].
(ii)Stimulation of TGF-b production by renal cells
[174] and fibrosis [175,176].
(iii)Renal vasoconstriction that diminishes renal
blood flow with two consequences: on the one hand
it diminishes glomerular filtration, and on the other,
it may lead to oxygen deficit and hypoxia in deter-
mined circumstances. Hypoxia sensitizes cells to cell
death and activates the release of HIF, which pro-
motes fibrosis [131-133]. Besides, hypoxia limits the
cell’sA T Pr e s e r v ea n dt h u si tm a yc h a n g et h ec e l l
death phenotype to necrosis [177], which in turn
further activates the immune response. Vasoconstric-
tion might be the result of endothelial dysfunction
and oxidative stress [178-180], and also of release of
contracting factors such as endothelin-1 and platelet
activating factor (PAF) by endothelial and mesangial
cells, and podocytes [181-184].
(iv)Microvascular congestion resulting from endothe-
lial dysfunction and aberrant coagulation, which
contributes to hypoxia [185,186].
(v)Mesangial contraction [181-184], causing the
ultrafiltration coefficient (Kf) and glomerular filtra-
tion to decrease [187].
Proliferating parietal epithelial cells (PECs) of
Bowman’s capsule have been involved in the develop-
ment of FSGS, and in extracapillary proliferation. Long
considered passive bystanders in CKD, in recent years
several studies have shown that PECs proliferate and
produce ECM components contributing to fibrosis,
adhesions of glomerular capillary to Bowman’s capsule
[188,189], and glomerular collapse, in different glomeru-
lar diseases. In addition, PECs can become activated and
express many growth factors, chemokines, cytokines,
and their receptors [reviewed in [190]].
Finally, podocytes have progressively gained central
a t t e n t i o ni ng l o m e r u l o p a t h i e sa n da r ec o n s i d e r e dt o
have a central role in the pathological process, as a
result of both genetic and acquired alterations. Loss of
podocytes, which lack the ability of postnatal prolifera-
tion, has been implicated in the progression of glomeru-
lar diseases to glomerulosclerosis [191]. Podocytes are
specialized pericytes placed around the glomerular capil-
laries, which contribute to the special characteristics of
the glomerular filtration barrier [148,192]. Human
acquired proteinuric glomerulopathies, such as diabetic
nephropathy, minimal-change nephrotic syndrome
(MCNS), FSGS, and membranous nephropathy (MN),
commonly exhibit foot process effacement of podocytes
and loss of slit diaphragms in electron microscopy; these
glomerulopathies therefore are considered as podocyte
injury diseases (podocytopathies) [148,193]. Several
experimental models, such as rat puromycin aminonu-
cleoside (PAN) nephropathy and mouse adriamycin
(ADR) nephropathy that develop massive proteinuria
resembling human minimal change disease, have pro-
vided insights into the cellular and intracellular mechan-
isms of podocyte injury disease.
Podocyte dysfunction leads to progressive renal insuf-
ficiency. First, podocyte damage causes proteinuria. Sus-
tained proteinuria gives rise to tubulointerstitial injury,
eventually leading to renal failure [194]. Second, podo-
cyte injury impairs mesangial structure and function. In
anti-Thy-1 glomerulonephritis, the induction of minor
podocyte injury with PAN pretreatment results in an
irreversible mesangial alteration [195]. In addition,
cysteine-rich protein 61 (Cyr61), a potent angiogenic
protein that belongs to the CCN family of matrix-
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cytes and upregulated in anti-Thy-1 glomerulonephritis
[196]. Cyr61 inhibits mesangial cell migration, suggest-
i n gt h a tC y r 6 1m a yp l a yam o d u l a t o r yr o l ei nl i m i t i n g
mesangial activation. Thus, podocytes may secrete var-
ious humoral factors that regulate mesangial structure
and function, and their reduction could result in
impaired mesangial function, mesangial proliferation
and matrix expansion. For example, angiotensin II and
high glucose exposure increase podocyte production of
TGF-b1 [197] and VEGF [198], both of which are
known to affect mesangial cells [199]. Third, podocyte
loss or detachment from the glomerular basement mem-
brane leads to glomerulosclerosis [200]. In human
diabetic nephropathy and IgA nephropathy, decreased
podocyte number correlates significantly with poor
prognosis [201,202]. These data suggest that podocyte
injury is critical not only in podocyte-specific diseases
such as MCNS and FSGS but also in podocyte-nonspe-
cific diseases such as IgA and diabetic nephropathy.
Renovascular diseases
Renovascular diseases comprise a group of progressive
conditions involving renal dysfunction and renal damage
derived from the narrowing or blockage of the renal
blood vessels. According to the U.S. Renal Data System
[203], about one third of all ESRD cases were related to
renovascular diseases. Renovascular diseases usually
Figure 5 Glomerular effects of inflammation. ET-1, endothelin 1. HIF, hypoxia inducible factor. Kf, ultrafiltration coefficient. OFR, oxygen free
radicals. PAF, platelet activating factor. RBF, renal blood flow. TGF-b, tumor growth factor beta. TXA2, thromboxane A2.
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occlusion, renal vein thrombosis, and renal atheroembo-
lism are also potential causes. The term is most often
used to describe diseases affecting the renal arteries,
because blockage of the renal veins is not very common.
Renovascular alterations affect the main renal arteries
and their branches (stenosis) or microvessels (throm-
boembolic microangiopathy) and lead to CKD. Athero-
sclerosis induces 70-90% of cases of renal stenosis and
is the predominant lesion detected in patients >50 years
of age [204,205], whereas most remaining cases are
caused by fibromuscular dysplasia. The latter is a group
of idiopathic fibrotic conditions affecting especially the
media, but also the intima and the adventitial layers of
small vessels, which is more frequent in middle-aged
women. Unusual causes of stenosis are external pressure
(e.g. exerted by a tumor), partial occlusion at the suture
level after renal transplant, as well as nephroangiosclero-
sis (hypertensive injury), diabetic nephropathy (in small
vessels), renal thromboembolic disease, atheroembolic
renal disease, aortorenal dissection, renal artery vasculi-
tis, trauma, neurofibromatosis, thromboangiitis obliter-
ans and scleroderma [206,207]. CKD is a probable
outcome, although stenotic hypoperfusion is not synon-
ymous with renal disease. Surprisingly, stenosis caused
by fibromuscular dysplasia rarely provokes renal
damage, despite inducing intrarenal hemodynamic
changes and activating pressor mechanisms as well. On
t h ec o n t r a r y ,a t h e r o s c l e r o t i cs t e n o s i sm o r eo f t e nl e a d s
to CKD. Even moderate stenosis can (more rarely) give
rise to CKD. The likelihood of developing CKD asso-
ciated with atherosclerotic stenosis escalates with the
severity and persistence of the occlusion and with the
presence of comorbid factors [208].
As explained in the next paragraphs, renovascular
diseases may alter renal function and structure directly
through (i) atherosclerosis-initiated renal oxidative
stress, endothelial dysfunction and inflammation leading
to fibrosis and reduced filtration; (ii) creating hypoperfu-
sion and ischemic scenarios compromising renal
b l o o df l o w ,a n dt u b u l a ra n dg l o m e r u l a rf u n c t i o n ;a n d
(iii) indirectly, through the onset of hypertension.
Atherosclerosis and renal injury
Atherosclerosis of renal vessels has two main effects
leading independently and cooperatively to renal
dysfunction. On the one hand, atherosclerotic vessels
have an increased production of ROS that cause oxida-
tive stress. Oxidative stress has two main consequences:
(i) endothelial dysfunction, and (ii) inflammation. On
the other hand, large atherosclerotic formations may
reduce renal blood flow (in the whole kidney or in
specific areas) over the auto-regulatory window, and suf-
ficiently to reduce glomerular filtration [figure 6;
[209,210]]. Even in the absence of an important obstruc-
tion, endothelial dysfunction and inflammation can
cause glomerular filtration to decrease. Endothelial dys-
function causes vasoconstriction and reduced renal
blood flow leading to reduced filtration. Inflammation
induces tubular and glomerular cell activation and the
production of vasoactive molecules, such as platelet acti-
vating factor (PAF), endothelin-1 and RAS activation
[143]. These mediators induce (i) vasoconstriction and
mesangial contraction (which reduces the ultrafiltration
coefficient, Kf) leading to the reduction of glomerular
filtration; and, in some circumstances (ii) cell death con-
tributing to nephron loss.
Increased production of ROS in pathological situations
such as hypertension and atherosclerosis is frequently
mediated by activation of the renin-angiotensin system
and NAD(P)H oxidase [211-213]. As Chade et al. [214]
showed that systemic plasma renin activity was not ele-
v a t e di na ni nv i v oe x p e r i m e n t a lm o d e lo fr e n o v a s c u l a r
disease, the intrarenal renin-angiotensin system seems to
be activated within the stenotic kidney. The angiotensin
II-induced ROS generation through activation of NAD(P)
H oxidase seems to involve a feed-forward mechanism
inducing a prolonged production of ROS [211]. Chronic
effects of oxidative stress play a relevant role in the
pathogenesis of renal injury in renovascular disease [214],
and oxidative stress clearly contributes to renovascular-
induced hypertension [215]. ROS may induce vasocon-
striction and modulate renal microvascular function
[216], contributing to the enhanced renal vascular tone
and sensitivity induced by other vasoconstrictors such as
angiotensin II and endothelin-1. Furthermore, superoxide
anion and nitric oxide (NO) may also react with each
other, which decreases NO availability and impairs
intrarenal vascular and glomerular function due to the
formation of peroxynitrite [213,216]. Finally, antioxidants
have shown to prevent the renal damage and dysfunction
induced by renal artery obstruction and atherosclerosis
[214]. All these facts suggest that increased oxidative
stress is involved, at least partially, in the impaired
endothelium-dependent vasodilatation observed in
patients with renovascular hypertension.
Renal injury due to hypoperfusion and ischemia
Severe occlusions decreasing over a 60% of renal flow,
lead to a reduction of renal perfusion pressure under
the autoregulatory range (< 70-85 mmHg). Renal hypo-
perfusion appears only when renal perfusion pressure
falls below the autoregulatory range, and thus renal
blood flow declines. It is estimated that a 70-80% of the
luminal area of the renal artery must be occluded for
hypoperfusion to occur, which is termed “critical steno-
sis” [217]. This condition induces a generalized tissue
hypoperfusion (sometimes referred to as ischemia) and
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quently to secondary FSGS) and CKD. Localized or
spread thromboembolic microangiopathy may also cause
focal or generalized true ischemic scenarios, which may
be the consequence of systemic atherosclerotic disease,
o rm a yb ei n d i r e c t l yp o t e n t i a t e db yi tt h r o u g hm a i n
renal artery atherosclerotic stenosis. Still, a severe
diminution of renal blood flow does not necessarily
cause an injuring ischemia, but it may merely lead to a
reversible, hibernating-like functional state and in some
cases to renal damage [208]. It must be born in mind
that just a mere 10% of total oxygen passing through
the kidney is used for its metabolic needs [218]. In this
situation, pressor mechanisms become invariably acti-
vated which raise systemic blood pressure and, conse-
quently, renal perfusion pressure to achieve water and
electrolyte balance (see 4.3.). Hypertension aggravates
the renal stenosis outcome [219]. In fact, a complex
relationship has been described among renal artery ste-
nosis, hypertension and CKD [220].
Severe renal hypoperfusion leads to microvascular rar-
efaction (MR) and deficient vascular endothelium
growth factor (VEGF) production and focal or spread
ischemia [221]. MR seems to play a significant role in
renovascular disease, because exogenous administration
of VEGF prevents MV and renal dysfunction [221].
Ischemia also is recognized as a strong injuring and
fibrogenic stimulus, but the mechanisms leading to
CKD are poorly understood [208]. HIF, which is a pro-
angiogenic and protective mediator in vivo released by
ischemic cells, has been demonstrated to promote renal
fibrosis in chronic pathological circumstances [222].
Figure 6 Initiating mechanisms in renovascular nephropathies. GFR, glomerular filtration rate. RBF, renal blood flow. ROS, reactive oxygen
species. TGF, tubulo-glomerular feedback
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injury [223]. Decreased O2 and glucose supply limit
ATP production, which leads or predisposes cells to
dying [224-226]. Hypoxia also activates inducible nitric
oxide synthase (iNOS) expression, which produces oxi-
dative stress, inhibits ATP synthesis and activates apop-
tosis [227].
Hypertensive injury
Hypertension is a prospective inducer of renal damage
in stenotic kidneys [228]. Hypertensive nephropathy is a
glomerulopathy initiated by the increase in intraglomeu-
lar pressure, which activates and damages glomerular
cells, including mesangial and epithelial cells and
podocytes. These cells produce proinflammatory and
vasoactive mediators that contribute to cell damage and
fibrosis, reduce renal blood flow, Kf, and glomerular
filtration (as described in general for glomerulopathies
in section 3, and specifically in 143; and depicted in fig-
ure 6). Initially, hypertension-induced stress activates
the local RAS at the glomerular level. As in many other
cardiovascular pathological situations, local RAS has
been decisively implicated in tissue alteration and remo-
delling. Renal TGF-b,N F - B and other cytokines are
upregulated in a model of hypercholesterolemic renovas-
cular CKD [229], and also in a model of aortic coarcta-
tion between both renal arteries, which pathologically
resembles unilateral stenosis [230,231]. They might
mediate the inflammatory, fibrotic and apoptotic events,
as described generally for glomerular and tubular
diseases [208].
Renal artery stenosis may affect one kidney or both,
which induces different pathological scenarios [figure 7].
The case of a stenotic solitary kidney (as in unilaterally
nephrectomized or transplanted patients) is similar to
that of bilateral stenosis. In all cases, RAS plays a central
role in initiating compensatory responses that involve
systemic pressure rise [232]. In bilateral stenosis and
solitary stenosed kidneys the reduced perfusion pressure
induces a rapid release of renin that results in an
increased production of renal and systemic angiotensin
II. This, in turn, provokes a strong renal and systemic
vasoconstriction, and sodium and water tubular resorp-
tion that swiftly induce hypertension. Importantly, after
a few days, renin release by the stenotic kidney returns
to normal values, and hypertension becomes dependent
on extracellular (and blood) volume expansion and inde-
pendent from the RAS. Angiotensin converting enzyme
inhibitors (ACEIs) no longer affect blood pressure,
despite being capable of preventing its onset. If sodium
and water depletion is induced, hypertension becomes
newly renin-dependent [208,232]. RAS-mediated blood
pressure control is considered a medium term mechan-
ism. After that, pressure-natriuresis supersedes other
control mechanisms and even inactivates RAS-mediated
control [142], by turning down renin release [208,232].
In unilateral stenosis, the obstructed kidney responds
as in bilateral stenosis with renin release, angiotensin II
production and hypertension. In unilateral stenosis,
maintenance of hypertension is dependent on a con-
stantly activated RAS. High levels of circulating and
renal angiotensin II become increased [233], which
probably reset the pressure-natriuresis-diuresis mechan-
ism in the non stenotic kidney to higher levels of pres-
sure, so that water and electrolyte balance is achieved at
the new pressure. In fact, RAS blockers (e.g. angiotensin
converting enzyme inhibitors, ACEIs) inhibit both the
appearance and maintenance of hypertension in this
model [207]. It is noteworthy that angiotensin II is cap-
able of sustaining hypertension in the long term, as
demonstrated by the experimental rat hypertension
model induced by constant administration of angioten-
sin II [234]. In unilateral stenosis (and associated experi-
mental models, e.g. the Goldblatt experimental model of
unilateral stenosis, “two-kidney, one-clip” -2K1C-, and
the aortic coarctation between the renal arteries) the
non stenotic kidney also undergoes structural alterations
[230,231], probably as a consequence of the developed
hypertension, or as a result of the systemic or local
humoral alterations switched as a compensatory
response. In fact, TGF-b expression is upregulated as
well in the contralateral kidney by 3-5 weeks after
stenosis in 2K1C [235].
Merging mechanisms of progression
Irrespective of the cause, CKD pathogenesis is charac-
terized by a progressive loss of renal function, and an
excessive deposition of extracellular matrix in the glo-
meruli and tubular interstitium [236]. CKD progression
is associated with the appearance of an increasingly
commoner, fibrotic phenotype, where it is difficult to
determine the origin of the disease except for very
subtle morphological characteristics only available
through the pathological examination of renal biopsies.
This is because tubulointerstitial diseases ultimately
induce glomerular lesions, and glomerular diseases even-
tually cause tubulointerstitial damage. In both cases, the
result is a progressive nephron deletion and substitution
for scar-like tissue, which increasingly reduce glomerular
filtration and thus handicap renal excretory function.
Importantly, the degree of the renal lesion and the risk
of progression closely correlate with the extent of tubu-
lointerstitial fibrosis, regardless of etiology [69]. This
suggests that, at least initially, damaged glomeruli have
less impact in renal excretory function than damaged
tubuli. Damaged and sclerotic glomeruli may retain an
undetermined degree of filtration function which, due to
renal reserve, may cause a lower impact in the overall
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Page 16 of 26renal function. However, a mild dysfunction in tubular
reabsorption may lead to a dramatic fall in glomerular
filtration through the activation of the tubuloglomerular
feedback retrocontrol, in order to preserve hydroelectro-
lytic balance [237]. Furthermore, damaged tubuli may
get partially or totally obstructed by tissue debris result-
ing from epithelial destruction, which reduces or stops
filtration [figure 8]. Damaged tubuli produce a number
of pro-fibrotic and pro-inflammatory factors that, in
pathological circumstances, may also alter glomerular
function and damage glomeruli in a paracrine manner
(see table 2 and [143]).
Mechanisms traditionally suggested to connect primary
glomerulopathies with the subsequent pathological
recruitment of the tubulointerstitial space are [238]:
(i) an increased reabsorption of proteins in the proximal
tubules, resulting from glomerular hyperfiltration asso-
ciated with glomerular damage. An increased tubular
Figure 7 Pathophysiological events characteristic of the chronic phase of bilateral and unilateral stenotic renal disease.I nb o t hc a s e s ,
the hypoxia created by a substantially diminished renal blood flow and the hypertensive response are the dominant damaging mechanisms
(see text). RAS, renin-angiotensin system. TPR, total peripheral resistance. P-D, pressure diuresis. EMT, epithelial to mesenchymal transition.
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Page 17 of 26reabsorbtion of proteins activates the production of
cytokines by tubular cells, which, in turn, promotes the
infiltration of immune cells and the activation of an
immune-inflammatory response (238; and see the section
“Historical view” in 2). Abnormally filtered bioactive
macromolecules interact with proximal tubular epithelial
cells, activating signalling pathways that include NFkB
[239,240]. The megalin-cubilin complex mediates the
uptake of several proteins, including albumin, into proxi-
mal tubular epithelial cells. Megalin might also initiate or
participate in intracellular signalling linking abnormal
albuminuria with proinflammatory and profibrotic signal-
ing [240]. The neonatal Fc receptor and CD36 could also
play a role. Furthermore, addition of albumin or transfer-
rin to tubule cells reduces their ability to bind factor H
and counteract complement activation [241]. Albumin
can also be a source of potentially antigenic peptides
upon processing by renal dendritic cells [242]. Indeed,
proteinuria is not only a marker of disease, but also an
effector of nephropathy. Proteinuria correlates with dis-
ease progression, and pharmacological prevention of pro-
teinuria also correlates with progression slowing [2]; (ii)
direct encroachment of extracapillary lesions from the
glomerulus to the tubule [150]; (iii) recurring acute glo-
merular insults (as by toxics, metals, drugs, infections,
etc.) which perpetuate the production of growth factors
and chemokines involved in tubular damage [238]; (iv)
postglomerular malperfusion derived from the degrada-
tion, collapse or narrowing of glomerular capillaries,
resulting in tubular hypoxia [238]; (v) formation of para-
glomerular exudates containing profibrotic factors, ECM,
basement membrane material and tissue debris from
epithelial cells and podocytes, which reach the tubular
structures through interstitial routes and initiate an
injury process leading to tubulointerstitial fibrosis and
tubule degeneration that, in some instances, may lead to
the physical separation of the glomerulus and the tubule,
and the formation of a glomerular cyst [238]. Sclerotic
nuclei begin at glomerular adhesions formed by a glo-
merular capillary to Bowman’s capsule at a podocyte
deprived basement membrane point, which lead to the
formation of a paraglomerular space (PGS). PGS contains
ectopic filtrate and capillary tuft debris. The PGS content
is proposed to play a significant role in the initiation of
Figure 8 Pathological events linking glomerular and tubular injury, which lead to a progressively commoner phenotype as CKD
progresses.
López-Novoa et al. Journal of Translational Medicine 2011, 9:13
http://www.translational-medicine.com/content/9/1/13
Page 18 of 26damage and in the connection of glomerular and tubular
d i s e a s e s .I tm u s tb ep o i n t e do u tt h a ti n c r e a s i n ge v i d e n c e
suggests that even in traditionally considered glomerulo-
pathies, such as diabetic nephropathy, some degree of
tubular damage occurs before the first evidence of glo-
merular injury can be detected [243-247]. This may even-
tually force us to reshape our conceptual separation of
glomerular and tubular diseases into a more integrative
view [245].
Regardless of cause, as a consequence of the increas-
ing renal dysfunction, compensatory responses are
activated, which may also engage in the progressive
pathological vortex. These responses include hyperten-
sion and peripheral or renal sympathetic hyperactivity
[248], which are commonly observed in CKD patients.
Indeed, baroreceptor-mediated renal sympathetic
hyperactivity has been recently linked to the inception
and maintenance of hypertension [142]. Figure 8
compiles the pathological mechanisms connecting
tubular and glomerular damage, which set the basis of
a common renal pattern of disease during the progres-
sion of CKD.
Conclusions, clinical implications and perspectives
This review summarizes the key pathophysiological
events of CKDs compromising renal excretory function,
at the organism, tissue, cell and molecular levels. CKDs
may be originated in the glomeruli, in the tubuli or in
the renal vessels. Most of the diseases in each of these
groups have specific, but also common pathophysiologi-
cal characteristics resulting from increasingly under-
stood mechanisms of action. Moreover, all these
diseases, regardless of aetiology, eventually affect all
p a r t so ft h en e p h r o na n de n t e ra ni r r e v e r s i b l ec o u r s e
that may compromise the patient’s life. In addition, as
the disease progresses, a more uniform pathophysiologi-
cal pattern installs characterized by increasing fibrosis,
inflammation, nephron loss and parenchymal scarring.
Present treatments of CKD are only reasonably effective
at slowing progression. They are installed substantially
after irreversibility ensues, mostly because clear patholo-
gical signs only arise after over 50% of the nephrons are
functionally nulled. In these conditions, the earliest pos-
sible diagnosis is critical for prognosis. Moreover, the
identification of new biomarkers and technologies to
move progressively earlier the moment of diagnosis is
an active area of research.
The follow-up of CKD patients shows that the overall
death rate increases as kidney function decreases, and
the mortality in patients with ESRD remains 10-20
times higher than that in the general population. At pre-
sent there is no cure for CKD; the natural course of the
disease is to progress towards ESRD and death, unless
dialysis or transplant is implemented. The focus in
recent years has thus shifted to optimizing the care of
these patients during the phase of CKD, and to slow
progression with the aim of avoiding the necessity of
renal replacement therapy during the patient’s lifespan.
In many cases, it is possible to slow the progression of
CKD to ESRD if kidney disease is diagnosed and treated
in its earlier stages, mainly with renin-angiotensin sys-
tem blockers, although other drugs are under develop-
ment based on known mechanisms of progression
[143,249]. Thus, early CKD identification has potentially
enormous socioeconomic and medical benefits. Still, the
development of earlier diagnostic tools and better drugs
for preventing and, ideally, reversing renal damage and
restoring renal function needs a better knowledge of
pathophysiological mechanisms of CKD genesis and
progression. In this sense, reversal of CKD in the clinical
setting is still an unmet goal. However, promising
results have been obtained in some studies with experi-
mental models of renal fibrosis, for instance using BMP-
7 as a therapeutic agent [250,251].
Y e t ,av a l u a b l ea n dp o t e n t i a l l yu s e f u lp i e c eo fk n o w l -
edge for the clinical handling of CKD is still in the hori-
zon; namely understanding how and why an initial or
persistent insult to the kidney is not repaired but, on the
contrary, leads to an irreversible scenario of self destruc-
tion, which even becomes independent from the cause.
This no-return point in the fate of injured kidneys prob-
ably holds the key to a conceptual therapeutic drift from
slowing progression towards regression and, along with a
sufficiently early diagnosis, prevention entering the
vicious circle of deterioration. As it has been suggested
that an imbalance of pro-fibrotic and anti-fibrotic cyto-
kines is in the core of the no-return point [110], it would
be helpful to focus research efforts on this key aspect of
CKD, as a way to gain true control over this disease.
Declaration of competing interests
The authors declare that they have no competing interests.
Author details
1Instituto de Estudios de Ciencias de la Salud de Castilla y León (IECSCYL),
Soria, Spain.
2Unidad de Investigación, Hospital Universitario de Salamanca,
Salamanca, Spain.
3Unidad de Fisiopatología Renal y Cardiovascular.
Departamento de Fisiología y Farmacología, Universidad de Salamanca,
Spain.
4National Institutes of Health, Bethesda MD, USA.
5Renal and Vascular
Research Laboratory, IIS-Fundación Jiménez Díaz and Universidad Autonoma
de Madrid, Madrid, Spain.
6Instituto Reina Sofía de Investigación Nefrológica,
Fundación Íñigo Álvarez de Toledo, Madrid, Spain.
Authors’ contributions
JML-N drafted the manuscript and contributed with specific information and
critical analysis through the manuscript. ABR-P provided most of the
information on tubulointerstitial diseases. AO introduced the clinical scope
to the manuscript and specific aspects of sections 1 and 2.3. CM-S
incorporated a part of the information in sections 3 and 4, provided specific
pieces of information through the manuscript and critically helped with the
draft. FJL-H delineated and wrote most of the manuscript, composed the
figures and integrated the information into sections 5 and 6. All authors
read and approved the final manuscript.
López-Novoa et al. Journal of Translational Medicine 2011, 9:13
http://www.translational-medicine.com/content/9/1/13
Page 19 of 26Received: 6 August 2010 Accepted: 20 January 2011
Published: 20 January 2011
References
1. Mitch WE, Walser M, Buffington GA, Lemann J Jr: A simple method of
stimating progression of chronic renal failure. Lancet 1976, 2:1326-1328.
2. Remuzzi G, Benigni A, Remuzzi A: Mechanisms of progression and
regression of renal lesions of chronic nephropathies and diabetes. J Clin
Invest 2006, 116:288-296.
3. Chin C: Renal failure: Pharmacologic issues. Pharmacy Practice 2002, 1-8.
4. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ,
Perrone RD, Lau J, Eknoyan G, National Kidney Foundation: National
Kidney Foundation practice guidelines for chronic kidney disease:
evaluation, classification, and stratification. Ann Intern Med 2003,
139:137-147.
5. Snively CS, Gutierrez C: Chronic kidney disease: Prevention and treatment
of chronic complications. American Family Physician 2004, 70:1921-1928.
6. Snyder S, Pendergraph B: Detection and evaluation of chronic kidney
disease. American Family Physician 2005, 72:1723-1732.
7. Feig DI: Uric acid: a novel mediator and marker of risk in chronic kidney
disease? Curr Opin Nephrol Hypertens 2009, 18:526-530.
8. Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J,
Rincón A, Arroyo D, Luño J: Effect of allopurinol in chronic kidney disease
progression and cardiovascular risk. Clin J Am Soc Nephrol 2010,
5:1388-1393.
9. Bellomo G, Venanzi S, Verdura C, Saronio P, Esposito A, Timio M:
Association of uric acid with change in kidney function in healthy
normotensive individuals. Am J Kidney Dis 2010, 56:264-272.
10. Brenner BM: Nephron adaptation to renal injury or ablation. Am J Physiol
1985, 249:F324-337, (1985).
11. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH,
Steffes MW: American Diabetes Association. Nephropathy in diabetes.
Diabetes Care 2004, 7(Suppl 1):S79-83.
12. , U.S. Renal Data System, USRDS 2009 Annual Data Report: Atlas of Chronic
Kidney Disease and End-Stage Renal Disease in the United States, National
Institutes of Health, National Institute of Diabetes and Digestive and Kidney
Diseases, Bethesda, MD, 2009.
13. Brosnahan G, Fraer M: Chronic kidney disease: whom to screen and how
to treat, part 1: definition, epidemiology, and laboratory testing. South
Med J 2010, 103:140-146.
14. Stengel B, Tarver-Carr ME, Powe NR, Eberhardt MS, Brancati FL: Lifestyle
factors, obesity and the risk of chronic kidney disease. Epidemiology 2003,
14:479-487.
15. Hsu CY, Mc Culloch ChE, Iribarren C, Darbinian J, Go AS: Body mass
index and risk for end-stage renal disease. A n nI n t e r nM e d2006,
144:21-28.
16. Ejerblad E, Foerd M, Lindblad P, Fryzek J, McLaughlin JK, Nyrén O: Obesity
and risk for chronic renal failure. J Am Soc Nephrol 2006, 17:1695-1702.
17. Ritz E: Metabolic syndrome and kidney disease. Blood Purif 2008, 26:59-62.
18. Hall JE, Crook ED, Jones DW, Wofford MR, Dubbert PM: Mechanisms of
obesity-associated cardiovascular and renal disease. Am J Medical
Sciences 2002, 324:127-137.
19. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V,
Whelton PK, He J: The metabolic syndrome and chronic kidney disease
in U.S. adults. Ann Intern Med 2004, 140:167-174.
20. Ting SM, Nair H, Ching I, Taheri S, Dasgupta I: Overweight, obesity and
chronic kidney disease. Nephron Clin Pract 2009, 112:c121-127.
21. Faronato PP, Maioli M, Tonolo G, Brocco E, Noventa F, Piarulli F,
Abaterusso C, Modena F, de Bigontina G, Velussi M, Inchiostro S,
Santeusanio F, Bueti A, Nosadini R: Clusterin of albumin excretion rate
abnormalities in Caucassian patients with NIDDM. The Italian NIDDM
nephropathy study group. Diabetologia 1997, 40:816-823.
22. Satko SG, Freedman BI: The importance of family history on the
development of renal disease. Curr Opin Nephrol Hypertens 2004,
13:337-341.
23. Gohda T, Tanimoto M, Watanabe-Yamada K, Matsumoto M, Kaneko S,
Hagiwara S, Shiina K, Shike T, Funabiki K, Tomino Y: Genetic susceptibility
to type 2 diabetic nephropathy in human and animal models.
Nephrology (Carlton) 2005, 10(Suppl):S22-25.
24. Satko SG, Freedman BI, Moossavi S: Genetic factors in end-stage renal
disease. Kidney Int Suppl 2005, 94:S46-49.
25. Kao WH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, Li M, Coresh J,
Patterson N, Tandon A, Powe NR, Fink NE, Sadler JH, Weir MR, Abboud HE,
Adler SG, Divers J, Iyengar SK, Freedman BI, Kimmel PL, Knowler WC,
Kohn OF, Kramp K, Leehey DJ, Nicholas SB, Pahl MV, Schelling JR, Sedor JR,
Thornley-Brown D, Winkler CA, Smith MW, Parekh RS: Family Investigation
of Nephropathy and Diabetes Research Group. MYH9 is associated with
nondiabetic end-stage renal disease in African Americans. Nat Genet
2008, 40:1185-1192.
26. Freedman BI, Hicks PJ, Bostrom MA, Cunningham ME, Liu Y, Divers J,
Kopp JB, Winkler CA, Nelson GW, Langefeld CD, Bowden DW:
Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9)
are strongly associated with end-stage renal disease historically
attributed to hypertension in African Americans. Kidney Int 2009,
75:736-745.
27. Divers J, Freedman BI: Susceptibility genes in common complex kidney
disease. Curr Opin Nephrol Hypertens 2010, 19:79-84.
28. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI,
Bowden DW, Langefeld CD, Oleksyk TK, Uscinski Knob AL, Bernhardy AJ,
Hicks PJ, Nelson GW, Vanhollebeke B, Winkler CA, Kopp JB, Pays E,
Pollak MR: Association of trypanolytic ApoL1 variants with kidney disease
in African Americans. Science 2010, 329:841-845.
29. Tsukaguchi H, Sudhakar A, Le TC, Nguyen T, Yao J, Schwimmer JA,
Schachter AD, Poch E, Abreu PF, Appel GB, Pereira AB, Kalluri R, Pollak MR:
NPHS2 mutations in late-onset focal segmental glomerulosclerosis:
R229Q is a common disease-associated allele. J Clin Invest 2002,
110:1659-1666.
30. Franceschini N, North KE, Kopp JB, McKenzie L, Winkler C: NPHS2 gene,
nephrotic syndrome and focal segmental glomerulosclerosis: a HuGE
review. Genet Med 2006, 8:63-75.
31. Brown EJ, Schlöndorff JS, Becker DJ, Tsukaguchi H, Tonna SJ, Uscinski AL,
Higgs HN, Henderson JM, Pollak MR: Mutations in the formin gene INF2
cause focal segmental glomerulosclerosis. Nat Genet 2010, 42:72-76.
32. Mukerji N, Damodaran TV, Winn MP: TRPC6 and FSGS: the latest TRP
channelopathy. Biochim Biophys Acta 2007, 1772:859-868.
33. Korstanje R, DiPetrillo K: Unraveling the genetics of chronic kidney
disease using animal models. Am J Physiol Renal Physiol 2004, 287:
F347-352.
34. Imperatore G, Hanson RL, Pettitt DJ, Kobes S, Bennett PH, Knowler WC: Sib-
pair linkage analysis for susceptibility genes for microvascular
complications among Pima Indians with type 2 diabetes. Pima Diabetes
Genes Group. Diabetes 1998, 47:821-830.
35. DeWan AT, Arnett DK, Atwood LD, Province MA, Lewis CE, Hunt SC,
Eckfeldt J: A genome scan for renal function among hypertensives: the
HyperGEN study. Am J Hum Genet 2001, 68:136-144.
36. Perez-Luque E, Malacara JM, Olivo-Diaz A, Aláez C, Debaz H, Vázquez-
Garcia M, Garay ME, Nava LE, Burguete A, Gorodezky C: Contribution
of HLA class II genes to end stage renal disease in mexican
patients with type 2 diabetes mellitus. Hum Immunol 2000,
61:1031-1038.
37. Dyck R, Bohm C, Klomp H: Increased frequency of HLA A2/DR4 and A2/
DR8 haplotypes in young saskatchewan aboriginal people with diabetic
end-stage renal disease. Am J Nephrol 2003, 23:178-185.
38. Freedman BI, Spray BJ, Dunston GM, Heise ER: HLA associations in end-
stage renal disease due to membranous glomerulonephritis: HLA-DR3
associations with progressive renal injury. Southeastern Organ
Procurement Foundation. Am J Kidney Dis 1994, 23:797-802.
39. Cogan MG, Medical Staff Conference: Tubulo-interstitial nephropathies–a
pathophysiologic approach. West J Med 1980, 132:134-140.
40. Strutz F, Neilson EG: The role of lymphocytes in the progression of
interstitial disease. Kidney Int Suppl 1994, 45:S106-110.
41. Braden GL, O’Shea MH, Mulhern JG: Tubulointerstitial diseases.
Am J Kidney Dis 2005, 46:560-572.
42. Norman JT, Fine LG: Progressive renal disease: fibroblasts, extracellular
matrix, and integrins. Exp Nephrol 1999, 7:167-177.
43. Okoń K, Sułowicz W, Smoleński O, Sydor A, Chruściel B, Kirker-Nowak A,
Rosiek Z, Sysło K, Stachura J: Interstitial, tubular and vascular factors in
progression of primary glomerulonephritis. Pol J Pathol 2007, 58:73-78.
44. Piscator M: Early detection of tubular dysfunction. Kidney Int 1991, 34:
S15-17.
45. Blythe WB: Natural history of hypertension in renal parenchymal disease.
Am J Kidney Dis 1985, 5:A50-56.
López-Novoa et al. Journal of Translational Medicine 2011, 9:13
http://www.translational-medicine.com/content/9/1/13
Page 20 of 2646. Rosario RF, Wesson DE: Primary hypertension and nephropathy. Curr Opin
Nephrol Hypertens 2006, 15:130-134.
47. Sugiura T, Wada A: Resistive index predicts renal prognosis in chronic
kidney disease. Nephrol Dial Transplant 2009, 24:2780-2785.
48. Mujais S, Batlle DC: Functional correlates of tubulo-interstitial damage.
Semin Nephrol 1988, 8:94-99.
49. Eknoyan G, Qunibi WY, Grissom RT, Tuma SN, Ayus JC: Renal papillary
necrosis: an update. Medicine (Baltimore) 1982, 61:55-73.
50. Kelly CJ: Cellular immunity and the tubulointerstitium. Semin Nephrol
1999, 19:182-187.
51. Eddy AA: Molecular insights into renal interstitial fibrosis. J Am Soc
Nephrol 1996, 7:2495-508.
52. Johnson DW, Saunders HJ, Baxter RC, Field MJ, Pollock CA: Paracrine
stimulation of human renal fibroblasts by proximal tubule cells. Kidney
Int 1998, 54:747-757.
53. Klahr S, Morrissey JJ: The role of growth factors, cytokines, and vasoactive
compounds in obstructive nephropathy. Semin Nephrol 1998, 18:622-632.
54. Palmer BF: The renal tubule in the progression of chronic renal failure. J
Investig Med 1997, 45:346-361.
55. Wardle EN: Modulatory proteins and processes in alliance with immune
cells, mediators, and extracellular proteins in renal interstitial fibrosis.
Ren Fail 1999, 21:121-133.
56. Nony PA, Schnellmann RG: Interactions between collagen IV and
collagen-binding integrins in renal cell repair after sublethal injury. Mol
Pharmacol 2001, 60:1226-1234.
57. Liu Y: Epithelial to mesenchymal transition in renal fibrogenesis:
pathologic significance, molecular mechanism, and therapeutic
intervention. J Am Soc Nephrol 2004, 15:1-12.
58. Lopez-Novoa JM, Nieto MA: Inflammation and EMT: an alliance towards
organ fibrosis and cancer progression. EMBO Mol Med 2009, 1:303-314.
59. Iwano M, Plieth D, Danoff TM, Xue C, Okada H, Neilson EG: Evidence that
fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest
2002, 110:341-350.
60. Zeisberg M, Kalluri R: The role of epithelial-to-mesenchymal transition in
renal fibrosis. J Mol Med 2004, 82:175-181.
61. Grande MT, López-Novoa JM: Fibroblast activation and myofibroblast
generation in obstructive nephropathy. Nat Rev Nephrol 2009, 5:319-328.
62. Zeisberg M, Duffield JS: Resolved: EMT produces fibroblasts in the kidney.
J Am Soc Nephrol 2010, 21:1247-1253.
63. Humphreys BD, Valerius MT, Kobayashi A, Mugford JW, Soeung S,
Duffield JS, McMahon AP, Bonventre JV: Intrinsic epithelial cells repair the
kidney after injury. Cell Stem Cell 2008, 2:284-291.
64. Humphreys BD, Lin SL, Kobayashi A, Hudson TE, Nowlin BT, Bonventre JV,
Valerius MT, McMahon AP, Duffield JS: Fate tracing reveals the pericyte
and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol
2010, 176:85-97.
65. Becker GJ, Hewitson TD: The role of tubulointerstitial injury in chronic
renal failure. Curr Opin Nephrol Hypertens 2000, 9:133-138.
66. Gibbs SR, Goins RA, Belvin EL, Dimari SJ, Merriam AP, Bowling-Brown S,
Harris RC, Haralson MA: Characterization of the collagen phenotype of
rabbit proximal tubule cells in culture. Connect Tissue Res 1999, 40:173-188.
67. Matsumoto Y, Ueda S, Yamagishi S, Matsuguma K, Shibata R, Fukami K,
Matsuoka H, Imaizumi T, Okuda S: Dimethylarginine
dimethylaminohydrolase prevents progression of renal dysfunction by
inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a
rat model of chronic kidney disease. J Am Soc Nephrol 2007,
18:1525-1533.
68. Eddy AA: Progression in chronic kidney disease. Adv Chronic Kidney Dis
2005, 12:353-365.
69. Nath KA: Tubulointerstitial changes as a major determinant in the
progression of renal damage. Am J Kidney Dis 1992, 20:1-17.
70. Lan HY, Nikolic-Paterson DJ, Mu W, Atkins RC: Local macrophage
proliferation in the progression of glomerular and tubulointerstitial
injury in rat anti-GBM glomerulonephritis. Kidney Int 1995, 48:753-760.
71. Nath KA: The tubulointerstitium in progressive renal disease. Kidney Int
1998, 54:992-994.
72. Wang Y, Chen J, Chen L, Tay YC, Rangan GK, Harris DC: Induction of
monocyte chemoattractant protein-1 in proximal tubule cells by urinary
protein. J Am Soc Nephrol 1997, 8:1537-1545.
73. Grandaliano G, Gesualdo L, Ranieri E, Monno R, Montinaro V, Marra F,
Schena FP: Monocyte chemotactic peptide-1 expression in acute and
chronic human nephritides: a pathogenetic role in interstitial monocytes
recruitment. J Am Soc Nephrol 1996, 7:906-913.
74. Tesch GH, Maifert S, Schwarting A, Rollins BJ, Kelley VR: Monocyte
chemoattractant protein 1-dependent leukocytic infiltrates are
responsible for autoimmune disease in MRL-Fas(lpr) mice. J Exp Med
1999, 190:1813-1824.
75. Rodemann HP, Muller GA: Abnormal growth and clonal proliferation of
fibroblasts derived from kidneys with interstitial fibrosis. Proc Soc Exp Biol
Med 1990, 195:57-63.
76. Rodemann HP, Muller GA: Characterization of human renal fibroblasts in
health and disease: II. In vitro growth, differentiation, and collagen
synthesis of fibroblasts from kidneys with interstitial fibrosis. Am J Kidney
Dis 1991, 17:684-686.
77. El Nahas AM, Bello AK: Chronic kidney disease: the global challenge.
Lancet 2005, 365:331-340.
78. Chevalier RL: Obstructive nephropathy: towards biomarker discovery and
gene therapy. Nat Clin Pract Nephrol 2006, 2:157-168.
79. Essawy M, Soylemezoglu O, Muchaneta-Kubara EC, Shortland J, Brown CB,
el Nahas AM: Myofibroblasts and the progression of diabetic
nephropathy. Nephrol Dial Transplant 1997, 12:43-50.
80. Roberts IS, Burrows C, Shanks JH, Venning M, McWilliam LJ: Interstitial
myofibroblasts: predictors of progression in membranous nephropathy.
J Clin Pathol 1997, 50:123-127.
81. Boukhalfa G, Desmouliere A, Rondeau E, Gabbiani G, Sraer JD: Relationship
between alpha-smooth muscle actin expression and fibrotic changes in
human kidney. Exp Nephrol 1996, 4:241-247.
82. Strutz F, Okada H, Lo CW, Danoff T, Carone RL, Tomaszewski JE, Neilson EG:
Identification and characterization of a fibroblast marker: FSP1. J Cell Biol
1995, 130:393-405.
83. Schlondorff D: The role of chemokines in the initiation and progression
of renal disease. Kidney Int Suppl 1995, 49:S44-47.
84. Bohle A, Mackensen-Haen S, Wehrmann M: Significance of postglomerular
capillaries in the pathogenesis of chronic renal failure. Kidney Blood Press
Res 1996, 19:191-195.
85. Mezzano SA, Aros CA, Droguett A, Burgos ME, Ardiles LG, Flores CA,
Carpio D, Vío CP, Ruiz-Ortega M, Egido J: Renal angiotensin II up-
regulation and myofibroblast activation in human membranous
nephropathy. Kidney Int Suppl 2003, 86:S39-45.
86. García-Sánchez O, López-Hernández FJ, Lopez-Novoa JM: An integrative
view on the role of TGF-beta in the progressive tubular deletion
associated with chronic kidney disease. Kidney Int 2010, 77:950-955.
87. Eddy AA: Molecular basis of renal fibrosis. Pediatr Nephrol 2000,
15:290-301.
88. Liu Y: Renal fibrosis: new insights into the pathogenesis and
therapeutics. Kidney Int 2006, 69:213-217.
89. Singer AJ, Clark RA: Cutaneous wound healing. N Engl J Med 1999,
341:738-746.
90. Eddy AA: Role of cellular infiltrates in response to proteinuria. Am J
Kidney Dis 2001, 37:S25-29.
91. Nishida M, Fujinaka H, Matsusaka T, Price J, Kon V, Fogo AB, Davidson JM,
Linton MF, Fazio S, Homma T, Yoshida H, Ichikawa I: Absence of angiotensin
II type 1 receptor in bone marrow-derived cells is detrimental in the
evolution of renal fibrosis. J Clin Invest 2002, 110:1859-1868.
92. Van Goor H, Ding G, Kees-Folts D, Grond J, Schreiner GF, Diamond JR:
Macrophages and renal disease. Lab Invest 1994, 71:456-464.
93. Vleming LJ, Bruijn JA, van Es LA: The pathogenesis of progressive renal
failure. Neth J Med 1999, 54:114-128.
94. Gharaee-Kermani M, Wiggins R, Wolber F, Goyal M, Phan SH: Fibronectin is
the major fibroblast chemoattractant in rabbit anti-glomerular basement
membrane disease. Am J Pathol 1996, 148:961-967.
95. Eddy AA: Experimental insights into the tubulointerstitial disease
accompanying primary glomerular lesions. JA mS o cN e p h r o l1994, 5:1273-1277.
96. Van Vliet A, Baelde HJ, Vleming LJ, de Heer E, Bruijn JA: Distribution of
fibronectin isoforms in human renal disease. J Pathol 2001, 193:256-262.
97. Wells AF, Larsson E, Tengblad A, Fellström B, Tufveson G, Klareskog L,
Laurent TC: The localization of hyaluronan in normal and rejected
human kidneys. Transplantation 1990, 50:240-243.
López-Novoa et al. Journal of Translational Medicine 2011, 9:13
http://www.translational-medicine.com/content/9/1/13
Page 21 of 2698. Beck-Schimmer B, Oertli B, Pasch T, Wuthrich RP: Hyaluronan induces
monocyte chemoattractant protein-1 expression in renal tubular
epithelial cells. J Am Soc Nephrol 1998, 9:2283-2290.
99. Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO,
Boivin GP, Bouck N: Thrombospondin-1 is a major activator of TGF-beta1
in vivo. Cell 1998, 93:1159-1170.
100. Hugo C, Shankland SJ, Pichler RH, Couser WG, Johnson RJ: Thrombospondin
1 precedes and predicts the development of tubulointerstitial fibrosis in
glomerular disease in the rat. Kidney Int 1998, 53:302-311.
101. Diamond JR, Levinson M, Kreisberg R, Ricardo SD: Increased expression of
decorin in experimental hydronephrosis. Kidney Int 1997, 51:1133-1139.
102. Schaefer L, Hausser H, Altenburger M, Ugorcakova J, August C, Fisher LW,
Schaefer RM, Kresse H: Decorin, biglycan and their endocytosis receptor
in rat renal cortex. Kidney Int 1998, 54:1529-1541.
103. Gonzalez-Avila G, Vadillo-Ortega F, Perez-Tamayo R: Experimental diffuse
interstitial renal fibrosis. A biochemical approach. Lab Invest 1988,
59:245-252.
104. Border WA, Noble NA: Transforming growth factor beta in tissue fibrosis.
N Engl J Med 1994, 331:1286-1292.
105. Cheng J, Grande JP: Transforming growth factor-beta signal transduction
and progressive renal disease. Exp Biol Med (Maywood) 2002, 227:943-956.
106. Roberts AB, McCune BK, Sporn MB: TGF-beta: regulation of extracellular
matrix. Kidney Int 1992, 41:557-559.
107. Hultström M, Leh S, Skogstrand T, Iversen BM: Upregulation of tissue
inhibitor of metalloproteases-1 (TIMP-1) and procollagen-N-peptidase in
hypertension-induced renal damage. Nephrol Dial Transplant 2008,
23:896-903.
108. Kim H, Oda T, Lopez-Guisa J, Wing D, Edwards DR, Soloway PD, Eddy AA:
TIMP-1 deficiency does not attenuate interstitial fibrosis in obstructive
nephropathy. J Am Soc Nephrol 2000, 12:736-748.
109. Klahr S: Progression of chronic renal disease. Heart Dis 2001, 3:205-209.
110. García-Sánchez O, López-Hernández FJ, López-Novoa JM: An integrative
view on the role of TGF-beta in the progressive tubular deletion
associated with chronic kidney disease. Kidney Int 2010, 77:950-955.
111. Nangaku M: Chronic hypoxia and tubulointerstitial injury: a final
common pathway to end-stage renal failure. J Am Soc Nephrol 2006,
17:17-25.
112. Ortiz A, Lorz C, Egido J: The Fas ligand/Fas system in renal injury. Nephrol
Dial Transplant 1999, 14:1831-1834.
113. Kelly DJ, Stein-Oakley A, Zhang Y, Wassef L, Maguire J, Koji T, Thomson N,
Wilkinson-Berka JL, Gilbert RE: Fas-induced apoptosis is a feature of
progressive diabetic nephropathy in transgenic (mRen-2)27 rats:
attenuation with renin-angiotensin blockade. Nephrology 2004, 9:7-13.
114. Lorz C, Ortiz A, Justo P, González-Cuadrado S, Duque N, Gómez-Guerrero C,
Egido J: Proapoptotic Fas ligand is expressed by normal kidney tubular
epithelium and injured glomeruli. J Am Soc Nephrol 2000, 11:1266-1277.
115. Khan S, Koepke K, Jarad G, Schlessman K, Cleveland RP, Wang B,
Konieczkowski M, Schelling JR: Apoptosis and JNK activation are
differentially regulated by Fas expression level in renal tubular epithelial
cells. Kidney Int 2001, 60:65-76.
116. Jarad G, Wang B, Khan S, DeVore J, Miao H, Wu K, Nishimura SL, Wible BA,
Konieczkowski M, Sedor JR, Schelling JR: Fas activation induces renal
tubular epithelial cell beta 8 integrin expression and function in the
absence of apoptosis. J Biol Chem 2002, 277:47826-47833.
117. Santiago B, Galindo M, Palao G, Pablos JL: Intracellular regulation of Fas-
induced apoptosis in human fibroblasts by extracellular factors and
cycloheximide. J Immunol 2004, 172:560-566.
118. Miyajima A, Chen J, Lawrence C, Ledbetter S, Soslow RA, Stern J, Jha S,
Pigato J, Lemer ML, Poppas DP, Vaughan ED, Felsen D: Antibody to
transforming growth factor-beta ameliorates tubular apoptosis in
unilateral ureteral obstruction. Kidney Int 2000, 58:2301-2313.
119. Kelly DJ, Cox AJ, Tolcos M, Cooper ME, Wilkinson-Berka JL, Gilbert RE:
Attenuation of tubular apoptosis by blockade of the renin-angiotensin
system in diabetic Ren-2 rats. Kidney Int 2002, 61:31-39.
120. Bhaskaran M, Reddy K, Radhakrishanan N, Franki N, Ding G, Singhal PC:
Angiotensin II induces apoptosis in renal proximal tubular cells. Am J
Physiol Ren Physiol 2003, 284:F955-965.
121. Ortiz-Arduan A, Danoff TM, Kalluri R, González-Cuadrado S, Karp SL, Elkon K,
Egido J, Neilson EG: Regulation of Fas and Fas ligand expression in
cultured murine renal cells and in the kidney during endotoxemia.
Am J Physiol 1996, 271:F1193-1201.
122. Schelling JR, Nkemere N, Kopp JB, Cleveland RP: Fas-dependent fratricidal
apoptosis is a mechanism of tubular epithelial cell deletion in chronic
renal failure. Lab Invest 1998, 78:813-824.
123. Khan S, Cleveland RP, Koch CJ, Schelling JR: Hypoxia induces renal tubular
epithelial cell apoptosis in chronic renal disease. Lab Invest 1999,
79:1089-1099.
124. Koesters R, Kaissling B, Lehir M, Picard N, Theilig F, Gebhardt R, Glick AB,
Hähnel B, Hosser H, Gröne HJ, Kriz W: Tubular overexpression of
transforming growth factor-beta1 induces autophagy and fibrosis but
not mesenchymal transition of renal epithelial cells. Am J Pathol 2010,
177:632-643.
125. Sanz AB, Santamaria B, Ruiz Ortega M, Egido J, Ortiz A: Mechanisms of
renal apoptosis in health and disease. J Am Soc Nephrol 2008,
19:1634-1642.
126. Ichikawi I, Harris RC: Angiotensin actions in the kidney: renewed insight
into the old hormone. Kidney Int 1991, 40:583-596.
127. Wang CZ, Hsu YM, Tang MJ: Function of discoidin domain receptor I in
HGF-induced branching tubulogenesis of MDCK cells in collagen gel. J
Cell Physiol 2005, 203:295-304.
128. Hughes J: Life and death in the kidney: prospects for future therapy.
Nephrol Dial Transplant 2001, 16:879-882.
129. De Broe ME: Apoptosis in acute renal failure. Nephrol Dial Transplant 2001,
16(Suppl 6):23-26.
130. Nilakantan V, Maenpaa C, Jia G, Roman RJ, Park F: 20-HETE-mediated
cytotoxicity and apoptosis in ischemic kidney epithelial cells. Am J
Physiol Renal Physiol 2008, 294:F562-570.
131. Orphanides C, Fine LG, Norman JT: Hypoxia stimulates proximal tubular
cell matrix production via a TGF-beta1-independent mechanism. Kidney
Int 1997, 52:637-647.
132. Haase VH: Pathophysiological Consequences of HIF Activation: HIF as a
modulator of fibrosis. Ann N Y Acad Sci 2009, 1177:57-65.
133. López-Novoa JM, Nieto MA: Inflammation and EMT: an alliance towards
organ fibrosis and cancer progression. EMBO Mol Med 2009, 1:303-314.
134. Serón D, Alexopoulos E, Raftery MJ, Hartley B, Cameron JS: Number of
interstitial capillary cross-sections assessed by monoclonal antibodies:
relation to interstitial damage. Nephrol Dial Transplant 1990, 5:889-893.
135. Couser WG: Pathogenesis of glomerular damage in glomerulonephritis.
Nephrol Dial Transplant 1998, 13:10-15.
136. Isaka Y, Akagi Y, Ando Y, Tsujie M, Imai E: Cytokines and
glomerulosclerosis. Nephrol Dial Transplant 1999, 14:30-32.
137. Nangaku M, Couser WG: Mechanisms of immune-deposit formation and
the mediation of immune renal injury. Clin Exp Nephrol 2005, 9:183-191.
138. Couser WG: Complement inhibitors and glomerulonephritis: are we there
yet? J Am Soc Nephrol 2003, 14:815-818.
139. Cunard R, Jelly CJ: Immune-mediated renal disease. J Allergy Clin Immunol
2003, 111:S637-644.
140. Shimizu A, Masuda Y, Kitamura H, Ishizaki M, Sugisaki Y, Yamanaka N:
Recovery of damaged glomerular capillary network with endothelial cell
apoptosis in experimental proliferative glomerulonephritis. Nephron 1998,
79:206-214.
141. , U.S. Renal Data System, USRDS 2005 Annual Data Report: Atlas of End-
Stage Renal Disease in the United States, National Institutes of Health,
National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda,
MD, 2005. http://www.usrds.org/atlas.htm.
142. López-Hernández FJ, López-Novoa JM: The lord of the ring: Mandatory
role of the kidney in drug therapy of hypertension. Pharmacol Ther 2006,
111:53-80.
143. López-Novoa JM, Martínez-Salgado C, Rodríguez-Peña AB, López
Hernández FJ: Common pathophysiological mechanisms of chronic
kidney disease: Therapeutic perspectives. Pharmacol Ther 2010, 128:61-81.
144. Tervaert TW, Mooyaart AL, Amann K, Cohen AH, Cook HT, Drachenberg CB,
Ferrario F, Fogo AB, Haas M, de Heer E, Joh K, Noël LH, Radhakrishnan J,
Seshan SV, Bajema IM, Bruijn JA, Renal Pathology Society: Pathologic
Classification of Diabetic Nephropathy. J Am Soc Nephrol 2010,
21:556-563.
145. Wesson LG: Physical factors and glomerulosclerosis. Cause or
coincidence? Nephron 1998, 78:125-130.
146. Wiggins RC: The spectrum of podocytopathies: a unifying view of
glomerular diseases. Kidney Int 2007, 71:1205-1214.
147. Ziyadeh FN, Wolf G: Pathogenesis of the podocytopathy and proteinuria
in diabetic glomerulopathy. Curr Diabetes Rev 2008, 4:39-45.
López-Novoa et al. Journal of Translational Medicine 2011, 9:13
http://www.translational-medicine.com/content/9/1/13
Page 22 of 26148. Moreno JA, Sanchez-Niño MD, Sanz AB, Lassila M, Holthofer H, Blanco-
Colio LM, Egido J, Ruiz-Ortega M, Ortiz A: A slit in podocyte death. Curr
Med Chem 2008, 15:1645-1654.
149. Kang YS, Li Y, Dai C, Kiss LP, Wu C, Liu Y: Inhibition of integrin-linked
kinase blocks podocyte epithelial-mesenchymal transition and
ameliorates proteinuria. Kidney Int 2010, 78:363-373.
150. Kriz W, LeHir M: Pathways to nephron loss starting from glomerular
diseases-insights from animal models. Kidney Int 2005, 67:404-419.
151. Harris RC, Akai Y, Yasuda T, Homma T: T h er o l eo fp h y s i c a lf o r c e si n
alterations of mesangial cell function. Kidney Int Suppl 1994, 45:
S17-21.
152. Funabiki K, Horikoshi S, Tomino Y, Nagai Y, Koide H: Immunohistochemical
analysis of extracellular components in the glomerular sclerosis of
patients with glomerulonephritis. Clin Nephrol 1990, 34:239-246.
153. Makino H, Kashihara N, Sugiyama H, Sekikawa T, Ota Z: Role of apoptosis
in the progression of glomerulosclerosis. Contrib Nephrol 1996, 118:41-47.
154. Kurogi Y: Mesangial cell proliferation inhibitors for the treatment of
proliferative glomerular disease. Med Res Rev 2003, 23:15-31.
155. Morel-Maroger Striker L, Killen PD, Chi E, Striker GE: The composition of
glomerulosclerosis. I. Studies in focal sclerosis, crescentic
glomerulonephritis, and membranoproliferative glomerulonephritis. Lab
Invest 1984, 51:181-192.
156. Floege J, Johnson RJ, Couser WG: Mesangial cells in the pathogenesis of
progressive glomerular disease in animal models. Clin Investig 1992,
70:857-864.
157. Massy ZA, Guijarro C, O’Donnell MP, Kim Y, Kashtan CE, Egido J, Kasiske BL,
Keane WF: The central role of nuclear factor-kappa B in mesangial cell
activation. Kidney Int 1999, 71:S76-79.
158. Johnson RJ, Alpers CE, Yoshimura A, Lombardi D, Pritzl P, Floege J,
Schwartz SM: Renal injury from angiotensin II-mediated hypertension.
Hypertension 1992, 19:464-474.
159. Ardaillou R, Chansel D, Chatziantoniou C, Dussaule JC: Mesangial AT1
receptors: expression, signaling, and regulation. J Am Soc Nephrol 1999,
10:S40-46.
160. Kagami S, Kondo S, Löster K, Reutter W, Kuhara T, Yasutomo K, Kuroda Y:
Alpha1beta1 integrin-mediated collagen matrix remodeling by rat
mesangial cells is differentially regulated by transforming growth factor-
beta and platelet-derived growth factor-BB. J Am Soc Nephrol 1999,
10:779-789.
161. Haberstroh U, Zahner G, Disser M, Thaiss F, Wolf G, Stahl RA: TGF-beta
stimulates rat mesangial cell proliferation in culture: role of PDGF beta-
receptor expression. Am J Physiol 1993, 264:F199-205.
162. Bessho K, Mizuno S, Matsumoto K, Nakamura T: Counteractive effects of
HGF on PDGF-induced mesangial cell proliferation in a rat model of
glomerulonephritis. Am J Physiol Renal Physiol 2003, 284:F1171-180.
163. Gomez-Garre D, Ruiz-Ortega M, Ortego M, Largo R, López-Armada MJ,
Plaza JJ, González E, Egido J: Effects and interactions of endothelin-1 and
angiotensin II on matrix protein expression and synthesis and mesangial
cell growth. Hypertension 1996, 27:885-892.
164. Hahn S, Krieg RJ Jr, Hisano S, Chan W, Kuemmerle NB, Saborio P, Chan JC:
Vitamin E suppresses oxidative stress and glomerulosclerosis in rat
remnant kidney. Pediatr Nephrol 1999, 13:195-198.
165. Jaimes EA, Galceran JM, Raij L: Angiotensin II induces superoxide anion
production by mesangial cells. Kidney Int 1998, 54:775-784.
166. Couser WG: Pathogenesis of glomerulonephritis. Kidney Int 1993, 42:
S19-26.
167. Grande MT, Perez-Barriocanal F, Lopez-Novoa JM: Role of inflammation in
túbulo-interstitial damage associated to obstructive nephropathy. J
Inflamm (Lond) 2010, 7:19.
168. Johnson RJ, Iida H, Alpers CE, Majesky MW, Schwartz SM, Pritzi P, Gordon K,
Gown AM: Expression of smooth muscle cell phenotype by rat
mesangial cells in immune complex nephritis. Alpha-smooth muscle
actin is a marker of mesangial cell proliferation. J Clin Invest 1991,
87:847-858.
169. Alpers CE, Hudkins KL, Gown AM, Johnson RJ: Enhanced expression of
“muscle-specific” actin in glomerulonephritis. Kidney Int 1992,
41:1134-1142.
170. Stokes MB, Holler S, Cui Y, Hudkins KL, Eitner F, Fogo A, Alpers CE:
Expression of decorin, biglycan, and collagen type I in human renal
fibrosing disease. Kidney Int 2000, 57:487-498.
171. Couser WG, Johnson RJ: Mechanisms of progressive renal disease in
glomerulonephritis. Am J Kidney Dis 1994, 23:193-198.
172. Justo P, Sanz AB, Sanchez-Niño MD, Winkles JA, Lorz C, Egido J, Ortiz A:
Cytokine cooperation in renal tubular cell injury: the role of TWEAK.
Kidney Int 2006, 70:1750-1758.
173. Sanchez-Niño MD, Benito-Martin A, Gonçalves S, Sanz AB, Ucero AC,
Izquierdo MC, Ramos AM, Berzal S, Selgas R, Ruiz-Ortega M, Egido J, Ortiz A:
TNF superfamily: a growing saga of kidney injury modulators. Mediators
Inflamm .
174. Strutz F, Neilson EG: New insights into mechanisms of fibrosis in immune
renal injury. Springer Semin Immunopathol 2003, 24:459-476.
175. Border WA, Noble NA: TGF-beta in kidney fibrosis: a target for gene
therapy. Kidney Int 1997, 51:1388-1396.
176. Tamaki K, Okuda S: Role of TGF-beta in the progression of renal fibrosis.
Contrib Nephrol 2003, 139:44-65.
177. Chiarugi A: ’’Simple but not simpler’’: toward a unified picture of energy
requirements in cell death. FASEB J 2005, 19:1783-1788.
178. Rusterholz C, Gupta AK, Huppertz B, Holzgreve W, Hahn S: Soluble factors
released by placental villous tissue: Interleukin-1 is a potential mediator
of endothelial dysfunction. Am J Obstet Gynecol 2005, 192:618-624.
179. Gao X, Zhang H, Belmadani S, Wu J, Xu X, Elford H, Potter BJ, Zhang C:
Role of TNF-alpha-induced reactive oxygen species in endothelial
dysfunction during reperfusion injury. Am J Physiol Heart Circ Physiol 2008,
295:H2242-2249.
180. Zhang C, Wu J, Xu X, Potter BJ, Gao X: Direct relationship between levels
of TNF-alpha expression and endothelial dysfunction in reperfusion
injury. Basic Res Cardiol 2010, 105:453-464.
181. Camussi G, Turello E, Tetta C, Bussolino F, Baglioni C: Tumor necrosis factor
induces contraction of mesangial cells and alters their cytoskeletons.
Kidney Int 1990, 38:795-802.
182. López-Farré A, Gómez-Garre D, Bernabeu F, Montañés I, Millás I, López-
Novoa JM: Renal effects and mesangial cell contraction induced by
endothelin are mediated by PAF. Kidney Int 1991, 39:624-630.
183. Bussolati B, Mariano F, Biancone L, Foà R, David S, Cambi V, Camussi G:
Interleukin-12 is synthesized by mesangial cells and stimulates platelet-
activating factor synthesis, cytoskeletal reorganization, and cell shape
change. Am J Pathol 1999, 154:623-632.
184. López-Novoa JM: Potential role of platelet activating factor in acute renal
failure. Kidney Int 1999, 55:1672-1682.
185. Molitoris BA, Sutton TA: Endothelial injury and dysfunction: role in the
extension phase of acute renal failure. Kidney Int 2004, 66:496-499.
186. Bonventre JV: Pathophysiology of AKI: injury and normal and abnormal
repair. Contrib Nephrol 2010, 165:9-17.
187. Rodriguez-Barbero A, L’Azou B, Cambar J, López-Novoa JM: Potential use of
isolated glomeruli and cultured mesangial cells as in vitro models to
assess nephrotoxicity. Cell Biol Toxicol 2000, 16:145-153.
188. Wolf G, Ziyadeh FN: Cellular and molecular mechanisms of proteinuria in
diabetic nephropathy. Nephron Physiol 2007, 106:p26-p31.
189. Ziyadeh FN, Wolf G: Pathogenesis of the podocytopathy and proteinuria
in diabetic glomerulopathy. Curr Diabetes Rev 2008, 4:39-45.
190. Smeets B, Dijkman H, Wetzels J, Steenbergen EJ: Lessons from studies on
focal segmental glomerulosclerosis: an important role for parietal
epithelial cells? J Pathol 2006, 210:263-272.
191. Asano T, Niimura F, Pastan I, Fogo AB, Ichikawa I, Matsusaka T: Permanent
genetic tagging of podocytes: fate of injured podocytes in a mouse
model of glomerular sclerosis. J Am Soc Nephrol 2005, 16:2257-2262.
192. Pätäri-Sampo A, Ihalmo P, Holthöfer H: Molecular basis of the glomerular
filtration: nephrin and the emerging protein complex at the podocyte
slit diaphragm. Ann Med 2006, 38:483-492.
193. Barisoni L, Mundel P: Podocyte biology and the emerging understanding
of podocyte diseases. Am J Nephrol 2003, 23:353-360.
194. Remuzzi G, Bertani T: Pathophysiology of progressive nephropathies. N
Engl J Med 1998, 339:1448-1456.
195. Morioka Y, Koike H, Ikezumi Y, Ito Y, Oyanagi A, Gejyo F, Shimizu F,
Kawachi H: Podocyte injuries exacerbate mesangial proliferative
glomerulonephritis. Kidney Int 2001, 60:2192-2204.
196. Sawai K, Mori K, Mukoyama M, Sugawara A, Suganami T, Koshikawa M,
Yahata K, Makino H, Nagae T, Fujinaga Y, Yokoi H, Yoshioka T, Yoshimoto A,
Tanaka I, Nakao K: Angiogenic protein Cyr61 is expressed by podocytes
in anti-Thy-1 glomerulonephritis. J Am Soc Nephrol 2003, 14:1154-1163.
López-Novoa et al. Journal of Translational Medicine 2011, 9:13
http://www.translational-medicine.com/content/9/1/13
Page 23 of 26197. Chen S, Kasama Y, Lee JS, Jim B, Marin M, Ziyadeh FN: Podocyte-derived
vascular endothelial growth factor mediates the stimulation of alpha3
(IV) collagen production by transforming growth factor-beta1 in mouse
podocytes. Diabetes 2004, 53:2939-2949.
198. Kang YS, Park YG, Kim BK, Han SY, Jee YH, Han KH, Lee MH, Song HK,
Cha DR, Kang SW, Han DS: Angiotensin II stimulates the synthesis of
vascular endothelial growth factor through the p38 mitogen activated
protein kinase pathway in cultured mouse podocytes. J Mol Endocrinol
2006, 36:377-388.
199. Wang L, Kwak JH, Kim SI, He Y, Choi ME: Transforming growth factor-
beta1 stimulates vascular endothelial growth factor 164 via mitogen-
activated protein kinase kinase 3-p38alpha and p38delta mitogen-
activated protein kinase-dependent pathway in murine mesangial cells.
J Biol Chem 2004, 279:33213-33219.
200. Kriz W, Gretz N, Lemley KV: Progression of glomerular diseases: Is the
podocyte the culprit? Kidney Int 1998, 54:687-697.
201. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD,
Rennke HG, Coplon NS, Sun L, Meyer TW: Podocyte loss and progressive
glomerular injury in type II diabetes. J Clin Invest 1997, 99:342-348.
202. Lemley KV, Lafayette RA, Safai M, Derby G, Blouch K, Squarer A, Myers BD:
Podocytopenia and disease severity in IgA nephropathy. Kidney Int 2002,
61:1475-1485.
203. U.S. Renal Data System, USRDS 2002 Annual Data Report: Atlas of End-Stage
Renal Disease in the United States, National Institutes of Health, National
Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2002.
204. Olin JW: Atherosclerotic renal artery disease. Cardiol Clin 2002, 20:547-562.
205. De Mast Q, Beutler JJ: The prevalence of atherosclerotic renal artery
stenosis in risk groups: a systematic literature review. J Hypertens 2009,
27:1333-1340.
206. Rihal CS, Textor SC, Breen JF, McKusick MA, Grill DE, Hallett JW, Holmes DR
Jr: Incidental renal artery stenosis among a prospective cohort of
hypertensive patients undergoing coronary angiography. Mayo Clin Proc
2002, 77:309-316.
207. Garovic VD, Textor SC: Renovascular hypertension and ischemic
nephropathy. Circulation 2005, 112:1362-1374.
208. Textor SC: Ischemic nephropathy: where are we now? J Am Soc Nephrol
2004, 15:1974-1982.
209. Chade AR, Rodriguez-Porcel M, Grande JP, Zhu X, Sica V, Napoli C,
Sawamura T, Textor SC, Lerman A, Lerman LO: Mechanisms of renal
structural alterations in combined hypercholesterolemia and renal artery
stenosis. Arterioscler Thromb Vasc Biol 2003, 23:1295-1301.
210. Chade AR, Lerman A, Lerman LO: Kidney in early atherosclerosis.
Hypertension 2005, 45:1042-1049.
211. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H: Role of
oxidative stress in atherosclerosis. Am J Cardiol 2003, 91:7-11A.
212. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK,
Harrison DG: Angiotensin II-mediated hypertension in the rat increases
vascular superoxide production via membrane NADH/NADPH oxidase
activation. Contribution to alterations of vasomotor tone. J Clin Invest
1996, 97:1916-1923.
213. Reckelhoff JF, Romero JC: Role of oxidative stress in angiotensin-induced
hypertension. Am J Physiol Regul Integr Comp Physiol 2003, 284:R893-912.
214. Chade AR, Krier JD, Rodriguez-Porcel M, Breen JF, McKusick MA, Lerman A,
Lerman LO: Comparison of acute and chronic antioxidant interventions
in experimental renovascular disease. Am J Physiol Renal Physiol 2004, 286:
F1079-1086.
215. Oliveira-Sales EB, Dugaich AP, Carillo BA, Abreu NP, Boim MA, Martins PJ,
D’Almeida V, Dolnikoff MS, Bergamaschi CT, Campos RR: Oxidative stress
contributes to renovascular hypertension. Am J Hypertens 2008, 21:98-104.
216. Schnackenberg CG: Physiological and pathophysiological roles of oxygen
radicals in the renal microvasculature. Am J Physiol Regul Integr Comp
Physiol 2002, 282:R335-342.
217. Textor SC, Novick AC, Tarazi RC, Klimas V, Vidt DG, Pohl M: Critical
perfusion pressure for renal function in patients with bilateral
atherosclerotic renal vascular disease. Ann Intern Med 1985, 102:308-314.
218. Epstein FH: Oxygen and renal metabolism. Kidney Int 1997, 51:381-385.
219. Spence JD: Treatment options for renovascular hypertension. Expert Opin
Pharmacother 2002, 3:411-416.
220. Safian RD, Textor SC: Renal-artery stenosis. N Engl J Med 2001, 344:431-442.
221. Iliescu R, Fernandez SR, Kelsen S, Maric C, Chade AR: Role of renal
microcirculation in experimental renovascular disease. Nephrol Dial
Transplant 2010, 25:1079-1087.
222. Haase VH: Pathophysiological Consequences of HIF Activation: HIF as a
modulator of fibrosis. Ann N Y Acad Sci 2009, 1177:57-65.
223. Moran K, Mulhall J, Kelly D, Sheehan S, Dowsett J, Dervan P, Fitzpatrick JM:
Morphological changes and alterations in regional intrarenal blood flow
induced by graded renal ischemia. J Urol 1992, 148:463-466.
224. Jeong JI, Lee YW, Kim YK: Chemical hypoxia-induced cell death in human
glioma cells: role of reactive oxygen species, ATP depletion,
mitochondrial damage and Ca2+. Neurochem Res 2003, 28:1201-1211.
225. Seppet E, Gruno M, Peetsalu A, Gizatullina Z, Nguyen HP, Vielhaber S,
Wussling MH, Trumbeckaite S, Arandarcikaite O, Jerzembeck D, Sonnabend M,
Jegorov K, Zierz S, Striggow F, Gellerich FN: Mitochondria and energetic
depression in cell pathophysiology. Int J Mol Sci 2009, 10:2252-2303.
226. Sato T, Oku H, Tsuruma K, Katsumura K, Shimazawa M, Hara H, Sugiyama T,
Ikeda T: Effect of hypoxia on susceptibility of RGC-5 cells to nitric oxide.
Invest Ophthalmol Vis Sci 2010, 51:2575-2486.
227. Kiang JG, Tsen KT: Biology of hypoxia. Chin J Physiol 2006, 49:223-233.
228. Voiculescu A, Grabensee B, Jung G, Mödder U, Sandmann W: Renovascular
disease: a review of diagnostic and therapeutic procedures. Minerva Urol
Nefrol 2006, 58:127-149.
229. Chade AR, Rodriguez-Porcel M, Grande JP, Zhu X, Sica V, Napoli C,
Sawamura T, Textor SC, Lerman A, Lerman LO: Mechanisms of renal
structural alterations in combined hypercholesterolemia and renal artery
stenosis. Arterioscler Thromb Vasc Biol 2003, 23:1295-1230.
230. Gallego B, Arevalo MA, Flores O, López-Novoa JM, Pérez-Barriocanal F:
Renal fibrosis in diabetic and aortic-constricted hypertensive rats. Am J
Physiol Regul Integr Comp Physiol 2001, 280:R1823-1829.
231. Gallego B, Arevalo , Flores O, López-Novoa JM, Pérez-Barriocanal F: Effect of
chronic and progressive aortic constriction on renal function and
structure in rats. Can J Physiol Pharmacol 2001, 79:601-607.
232. Textor SC: Pathophysiology of renovascular hypertension. Urol Clin North
Am 1984, 11:373-381.
233. Navar LG, Von Thun AM, Zou L, el-Dahr SS, Mitchell KD: Enhancement of
intrarenal angiotensin II levels in 2 kidney 1 clip and angiotensin II
induced hypertension. Blood Press Suppl 1995, 2:88-92.
234. Zimmerman MC, Lazartigues E, Sharma RV, Davisson RL: Hypertension
caused by angiotensin II infusion involves increased superoxide
production in the central nervous system. Circ Res 2004, 95:210-216.
235. Wolf G, Schneider A, Wenzel U, Helmchen U, Stahl RA: Regulation of
glomerular TGF-beta expression in the contralateral kidney of
two-kidney, one-clip hypertensive rats. J Am Soc Nephrol 1998,
9:763-772.
236. Bohle A, Muller GA, Wehrmann M, Mackensen-Haen S, Xiao JC:
Pathogenesis of chronic renal failure in the primary glomerulopathies,
renal vasculopathies, and chronic interstitial nephritides. Kidney Int Suppl
1996, 54:S2-9.
237. Komlosi P, Bell PD, Zhang ZR: Tubuloglomerular feedback mechanisms in
nephron segments beyond the macula densa. Curr Opin Nephrol
Hypertens 2009, 18:57-62.
238. Kriz W, Hosser H, Hahnel B, Gretz N, Provoost AP: From segmental
glomerulosclerosis to total nephron degeneration and interstitial
fibrosis: a histopathological study in rat models and human
glomerulopathies. Nephrol Dial Transplant 1998, 13:2781-2798.
239. Abbate M, Zoja C, Remuzzi G: How does proteinuria cause progressive
renal damage? J Am Soc Nephrol 2006, 17:2974-2984.
240. Baines RJ, Brunskill NJ: Tubular toxicity of proteinuria. Nat Rev Nephrol .
241. Buelli S, Abbate M, Morigi M, Moioli D, Zanchi C, Noris M, Zoja C, Pusey CD,
Zipfel PF, Remuzzi G: Protein load impairs factor H binding promoting
complement-dependent dysfunction of proximal tubular cells. Kidney Int
2009, 75:1050-1059.
242. Macconi D, Chiabrando C, Schiarea S, Aiello S, Cassis L, Gagliardini E,
Noris M, Buelli S, Zoja C, Corna D, Mele C, Fanelli R, Remuzzi G, Benigni A:
Proteasomal processing of albumin by renal dendritic cells generates
antigenic peptides. J Am Soc Nephrol 2009, 20:123-130.
243. Lapsley M, Flynn FV, Sansom PA: Beta 2-glycoprotein-1 (apolipoprotein H)
excretion and renal tubular malfunction in diabetic patients without
clinical proteinuria. J Clin Pathol 1993, 46:465-469.
López-Novoa et al. Journal of Translational Medicine 2011, 9:13
http://www.translational-medicine.com/content/9/1/13
Page 24 of 26244. Hong CY, Hughes K, Chia KS, Ng V, Ling SL: Urinary alpha1-microglobulin
as a marker of nephropathy in type 2 diabetic Asian subjects in
Singapore. Diabetes Care 2003, 26:338-342.
245. Thomas MC, Burns WC, Cooper ME: Tubular changes in early diabetic
nephropathy. Adv Chronic Kidney Dis 2005, 12:177-186.
246. Thomson SC, Vallon V, Blantz RC: Kidney function in early diabetes: the
tubular hypothesis of glomerular filtration. Am J Physiol Renal Physiol
2006, 286:F8-15.
247. Singh DK, Winocour P, Farrington K: Mechanisms of disease: the hypoxic
tubular hypothesis of diabetic nephropathy. Nat Clin Pract Nephrol 2008,
4:216-226.
248. Koomans HA, Blankestijn PJ, Joles JA: Sympathetic hyperactivity in chronic
renal failure: A wake-up call. J Am Soc Nephrol 2004, 15:524-537.
249. Perico N, Benigni A, Remuzzi G: Present and future drug treatments for
chronic kidney diseases: evolving targets in renoprotection. Nat Rev Drug
Discov 2008, 7:936-953.
250. Zeisberg M, Kalluri R: Reversal of experimental renal fibrosis by BMP7
provides insights into novel therapeutic strategies for chronic kidney
disease. Pediatr Nephrol 2008, 23:1395-1398.
251. Wang S, Chen Q, Simon TC, Strebeck F, Chaudhary L, Morrissey J, Liapis H,
Klahr S, Hruska KA: Bone morphogenic protein-7 (BMP-7), a novel therapy
for diabetic nephropathy. Kidney Int 2003, 63:2037-2049.
252. Leask A, Abraham DJ: TGF-β signaling and the fibrotic response. FASEB J
2004, 18:816-827.
253. Xu J, Lamouille S, Derynck R: TGF-beta-induced epithelial to mesenchymal
transition. Cell Res 2009, 19:156-172.
254. Wang SN, Lapage J, Hirschberg R: Glomerular ultrafiltration and apical
tubular action of IGF-I, TGF-beta, and HGF in nephrotic syndrome. Kidney
Int 1999, 56:1247-1251.
255. Duncan MR, Frazier KS, Abramson S, Williams S, Klapper H, Huang X,
Grotendorst GR: Connective tissue growth factor mediates transforming
growth factor beta-induced collagen synthesis: downregulation by
cAMP. FASEB J 1999, 13:1774-1786.
256. Okada H, Danoff TM, Kalluri R, Neilson EG: Early role of Fsp1 in epithelial-
mesenchymal transformation. Am J Physiol 1997, 273:F563-574.
257. Strutz F, Zeisberg M, Ziyadeh FN, Yang CQ, Kalluri R, Muller GA, Neilson EG:
Role of basic fibroblast growth factor-2 in epithelial-mesenchymal
transformation. Kidney Int 2002, 61:1714-1728.
258. Kriz W, Hahnel B, Rosener S, Elger M: Long-term treatment of rats with
FGF-2 results in focal segmental glomerulosclerosis. Kidney Int 1995,
48:1435-1450.
259. Phillips AO, Topley N, Morrisey K, Williams JD, Stedman R: Basic fibroblast
growth factor stimulates the release of preformed transforming growth
factor beta 1 from human proximal tubular cells in the absence of de
novo gene transcription or mRNA translation. Lab Invest 1997, 76:591-600.
260. Bonner JC: Regulation of PDGF and its receptors in fibrotic diseases.
Cytokine Growth Factor Rev 2004, 15:255-273.
261. Weston BS, Wahab NA, Mason RM: CTGF mediates TGF-beta-induced
fibronectin matrix deposition by upregulating active alpha5beta1
integrin in human mesangial cells. J Am Soc Nephrol 2003, 14:601-610.
262. Wahab NA, Weston BS, Mason RM: Modulation of the TGFbeta/Smad
signaling pathway in mesangial cells by CTGF/CCN2. Exp Cell Res 2005,
307:305-314.
263. Francki A, Bradshaw AD, Bassuk JA, Howe CC, Couser WG, Sage EH: SPARC
regulates the expression of collagen type I and transforming growth
factor-beta1 in mesangial cells. J Biol Chem 1999, 274:32145-32152.
264. Okada H, Danoff TM, Kalluri R, Neilson EG: Early role of Fsp1 in epithelial-
mesenchymal transformation. Am J Physiol 1997, 273:F563-F574.
265. Brown NJ, Vaughan DE, Fogo AB: Aldosterone and PAI-1: implications for
renal injury. J Nephrol 2002, 15:230-235.
266. Biancone L, David S, Della Pietra V, Montrucchio G, Cambi V, Camussi G:
Alternative pathway activation of complement by cultured human
proximal tubular epithelial cells. Kidney Int 1994, 45:451-460.
267. Tang S, Sheerin NS, Zhou W, Brown Z, Sacks SH: Apical proteins stimulate
complement synthesis by cultured human proximal tubular epithelial
cells. J Am Soc Nephrol 1999, 10:69-76.
268. Nangaku M, Pippin J, Couser WG: Complement membrane attack
complex (C5b-9) mediates interstitial disease in experimental nephrotic
syndrome. J Am Soc Nephrol 1999, 10:2323-2331.
269. Nomura A, Morita Y, Maruyama S, Hotta N, Nadai M, Wang L, Hasegawa T,
Matsuo S: Role of complement in acute tubulointerstitial injury of rats
with aminonucleoside nephrosis. Am J Pathol 1997, 151:539-547.
270. Hill PA, Lan HY, Nikolic-Paterson DJ, Atkins RC: ICAM-1 directs migration
and localization of interstitial leukocytes in experimental
glomerulonephritis. Kidney Int 1994, 45:32-42.
271. Ricardo SD, Levinson ME, DeJoseph MR, Diamond JR: Expression of
adhesion molecules in rat renal cortex during experimental
hydronephrosis. Kidney Int 1996, 50:2002-2010.
272. Ophascharoensuk V, Giachelli CM, Gordon K, Hughes J, Pichler R, Brown P,
Liaw L, Schmidt R, Shankland SJ, Alpers CE, Couser WG, Johnson RJ:
Obstructive uropathy in the mouse: role of osteopontin in interstitial
fibrosis and apoptosis. Kidney Int 1999, 56:571-580.
273. Zoja C, Morigi M, Figliuzzi M, Bruzzi I, Oldroyd S, Benigni A, Ronco P,
Remuzzi G: Proximal tubular cell synthesis and secretion of endothelin-1
on challenge with albumin and other proteins. Am J Kidney Dis 1995,
26:934-941.
274. Largo R, Gómez-Garre D, Soto K, Marrón B, Blanco J, Gazapo RM,
Plaza JJ, Egido J: Angiotensin-converting enzyme is upregulated in the
proximal tubules of rats with intense proteinuria. Hypertension 1999,
33:732-739.
275. Benigni A, Remuzzi G: How renal cytokines and growth factors contribute
to renal disease progression. Am J Kidney Dis 2001, 37(1 Suppl 2):S21-24.
276. Abe K, Li K, Sacks SH, Sheerin NS: The membrane attack complex, C5b-9,
up regulates collagen gene expression in renal tubular epithelial cells.
Clin Exp Immunol 2004, 136:60-66.
277. Justo P, Sanz AB, Sanchez-Niño MD, Winkles JA, Lorz C, Egido J, Ortiz A:
Cytokine cooperation in renal tubular cell injury: the role of TWEAK.
Kidney Int 2006, 70:1750-1758.
278. Wolfs TG, Buurman WA, van Schadewijk A, de Vries B, Daemen MA,
Hiemstra PS, van ‘t Veer C: In vivo expression of Toll-like receptor 2 and 4
by renal epithelial cells: IFN-gamma and TNF-alpha mediated up-
regulation during inflammation. J Immunol 2002, 168:1286-1293.
279. Guo G, Morrissey J, McCracken R, Tolley T, Liapis H, Klahr S: Contributions
of angiotensin II and tumor necrosis factor-alpha to the development of
renal fibrosis. Am J Physiol Renal Physiol 2001, 280:F777-785.
280. Longaretti L, Benigni A: Endothelin receptor selectivity in chronic renal
failure. Eur J Clin Invest 2009, 39(Suppl 2):32-37.
281. Kagami S, Border WA, Miller DE, Noble NA: Angiotensin II stimulates
extracellular matrix protein synthesis through induction of transforming
growth factor-beta expression in rat glomerular mesangial cells. J Clin
Invest 1994, 93:2431-2437.
282. Gilbert RE, Wu LL, Kelly DJ, Cox A, Wilkinson-BERKa JL, Johnston CI,
Cooper ME: Pathological expression of renin and angiotensin II in the
renal tubule after subtotal nephrectomy. Implications for the
pathogenesis of tubulointerstitial fibrosis. Am J Pathol 1999,
155:429-440.
283. Yang J, Dai C, Liu Y: Hepatocyte growth factor gene therapy and
angiotensin II blockade synergistically attenuate renal interstitial fibrosis
in mice. J Am Soc Nephrol 2002, 13:2464-2477.
284. Ursula C, Brewster MD, Mark A, Perazella MD: The renin-angiotensin-
aldosterone system and the kidney: effects on kidney disease. Am J Med
2004, 116:263-272.
285. Zeisberg M, Bonner G, Maeshima Y, Colorado P, Muller GA, Strutz F,
Kalluri R: Renal fibrosis: collagen composition and assembly regulates
epithelial-mesenchymal transdifferentiation. Am J Pathol 2001,
159:1313-1321.
286. Yang J, Liu Y: Dissection of key events in tubular epithelial to
myofibroblast transition and its implications in renal interstitial fibrosis.
Am J Pathol 2001, 159:1465-1475.
287. Liu Y: Hepatocyte growth factor promotes renal epithelial cell survival by
dual mechanisms. Am J Physiol 1999, 277:F624-633.
288. Yang J, Liu Y: Blockage of tubular epithelial to myofibroblast transition
by hepatocyte growth factor prevents renal interstitial fibrosis. J Am Soc
Nephrol 2002, 13:96-107.
289. Dworkin LD, Gong R, Tolbert E, Centracchio J, Yano N, Zanabli AR,
Esparza A, Rifai A: Hepatocyte growth factor ameliorates progression of
interstitial fibrosis in rats with established renal injury. Kidney Int 2004,
65:409-419.
López-Novoa et al. Journal of Translational Medicine 2011, 9:13
http://www.translational-medicine.com/content/9/1/13
Page 25 of 26290. Esposito C, Parrilla B, De Mauri A, Cornacchia F, Fasoli G, Foschi A,
Mazzullo T, Plati A, Scudellaro R, Dal Canton A: Hepatocyte growth factor
(HGF) modulates matrix turnover in human glomeruli. Kidney Int 2005,
67:2143-2150.
291. Vaidya VS, Ferguson MA, Bonventre JV: Biomarkers of acute kidney injury.
Annu Rev Pharmacol Toxicol 2008, 48:463-493.
doi:10.1186/1479-5876-9-13
Cite this article as: López-Novoa et al.: Etiopathology of chronic tubular,
glomerular and renovascular nephropathies: Clinical implications.
Journal of Translational Medicine 2011 9:13.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
López-Novoa et al. Journal of Translational Medicine 2011, 9:13
http://www.translational-medicine.com/content/9/1/13
Page 26 of 26